WO1999006049A1 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists

Info

Publication number
WO1999006049A1
WO1999006049A1 PCT/US1998/016246 US9816246W WO9906049A1 WO 1999006049 A1 WO1999006049 A1 WO 1999006049A1 US 9816246 W US9816246 W US 9816246W WO 9906049 A1 WO9906049 A1 WO 9906049A1
Authority
WO
WIPO (PCT)
Prior art keywords
6alkyl
crg
compound according
het
galkyl
Prior art date
Application number
PCT/US1998/016246
Other languages
French (fr)
Inventor
Dirk Heerding
James Martin Samanen
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP2000504863A priority Critical patent/JP2001511452A/en
Priority to EP98938357A priority patent/EP1007051A4/en
Priority to CA002298544A priority patent/CA2298544A1/en
Priority to AU86897/98A priority patent/AU8689798A/en
Publication of WO1999006049A1 publication Critical patent/WO1999006049A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to pharmaceutically active compounds which bind to integrins, such as dual antagonists of the vitronectin receptor and the fibrinogen receptor. Such compounds are useful for inhibiting platelet aggregation, treating restenosis and atherosclerosis and are useful in vascular remodeling.
  • Integrins are a family of heterodimeric proteins which generally mediate cell adhesion. Typical of such proteins are the vitronectin receptor (an ⁇ 3 heterodimer) and the fibrinogen receptor (an ⁇ b ⁇ 3 heterodimer).
  • the natural ligands of these receptors e.g., vitronectin and fibrinogen
  • vitronectin and fibrinogen have been found to share a common -Arg-Gly-Asp- amino acid sequence, which appears to be critical for binding.
  • many of the integrin receptors appear to cross react with ligands which possess such an amino acid sequence.
  • the ⁇ n b ⁇ 3 receptor reacts with fibronectin and vitronectin, thrombospondin and von Willebrand factor, as well as fibrinogen.
  • fibrinogen a dimer having two binding sites for ⁇ b ⁇ 3 , reacts with activated receptors found on the surface of platelets.
  • the binding of 0C ⁇ b ⁇ 3 receptors on adjacent platelets, by fibrinogen leads to crosslinking and is considered to be a major factor in platelet aggregation.
  • Compounds which inhibit the binding of the ⁇ b ⁇ 3 receptor to fibrinogen have been shown to inhibit the platelet aggregation in vitro, and thrombus formation in vivo.
  • the vitronectin receptor oty ⁇ ⁇ is expressed on a number of cells, including endothelial, smooth muscle, osteoclast, and tumor cells, and, thus, it has a variety of functions. It has been reported that the ⁇ v B 3 receptor expressed on human aortic smooth muscle cells stimulates their migration into neointima, which leads to the formation of atherosclerosis and restenosis after angioplasty. Brown, et al., Cardiovascular Res., 1994, 28, 1815. Additionally, a study has shown that a ⁇ y ⁇ ⁇ antagonist is able to promote tumor regression by inducing apoptosis of angiogenic blood vessels. Brooks, et al., Cell, 1994, 79, 1157.
  • agents that block the vitronectin receptor and the fibrinogen receptor would be useful in treating diseases mediated by these receptors, such as atherosclerosis, restenosis (Topol. et al., J. Am. Coll. Cardiol, 1996, 28, 1643.) and cancer.
  • This invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically carrier.
  • This invention is also a method of treating diseases in which the pathology may be modified by binding to integrin receptors, especially the vitronectin and the fibrinogen receptors.
  • the compounds of this invention are useful for treating atherosclerosis and restenosis, and conditions in which it is desirable to inhibit platelet aggregation, such as stroke, transient ischemia attacks, myocardial infarction and rethrombosis following thrombolytic therapy.
  • This invention comprises compounds of formulae (I) or (II):
  • A is NR', CHR', O or S
  • R 1 is R 7 , or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl,
  • R 2 is -(CH 2 )t-CO R 3 ;
  • R 3 isH, Ci_6alkylor(CHRVAr;
  • W is -(CHRg)a-U- (CHRg)b-;
  • Rg is H, C j ⁇ alkyl, Het-C()-6alkyl, C3-7cycloalkyl-C _6alkyl or Ar-CQ-6alkyl;
  • R k is Rg, -C(O)Rg, or -C(O)OR f ;
  • Ri is is H, C j .galkyl, Het-C ⁇ - ⁇ alkyl, C3-7cycloalkyl-Co-6alkyl, Ar-Co-6 a lkyl, or C j.galkyl substituted by one to three groups chosen from halogen, CN, NRg 2 , ORg, SRg, CO 2 Rg, and CON(Rg) 2 ; R f is H, C ⁇ _6alkyl or Ar-Cj.galkyl;
  • R e is H, Ci.galkyl, Ar-C ⁇ galkyl, Het-C ⁇ galkyl.
  • Cs- cycloalkyl-C galkyl, Rb and R c are independently selected from H, C j.galkyl, Ar-Co- ⁇ alkyl,
  • Q . Q ⁇ » Q 3 n d Q ⁇ are independently N or C-RY, provided that no more than one of Q ⁇ Q 2 , Q 3 and Q 4 is N;
  • RY is H, halo, -ORg, -SRg, -CN, -NRgR k , -NO 2 , -CF3, CF 3 S(O) r , -CO 2 Rg, -CORg or -CONRg 2 , or C 1 _6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR", -NO 2 , -CF3, R'S(O) r , -CO 2 Rg, -CORg or -CONRg 2 ;
  • R5 is W'-(CR , 2)q-Z-(CR'RlO) r -U'-(CR'2)s;
  • N CR', C(O) or O
  • Y is absent, S or O
  • Z is (CH 2 )t, Het. Ar or C3-7cycloalkyl
  • R 7 is -COR 8 , -COCR'2R 9 , -C(S)R 8 , -S(0) m OR , , -S(0) m NR'R", -PO(OR'), -PO(OR')2, ⁇ (OR ⁇ , -N0 2 and Tet;
  • R 8 is -OR', -NRR", -NR'SO2R', -NR'OR', -OCR'2C(O)OR', -OCR'2OC(O)- R', -OCR'2C(O)NR'2 or CF3;
  • R 9 is -OR', -CN, -S(O) r R', S(O) m NR'2, -C(O)R' C(O)NR'2 or -CO2R';
  • R 10 is H, C alkyl or -NRR"; each R u independently is H, halo, -OR 12 , -CN, -NR'R 12 , -NO 2 , -CF3, CF3S(O) r , -CO2R', -CONR'2, D-C ⁇ -6alkyl-, D-C ⁇ _6oxoalkyl-, D-C2-6alkenyl-, D-C2-6alkynyl-, D-C ⁇ -6alkyloxy-, D-C ⁇ -6alkylamino- or D-C ⁇ -6alkyl-S(O) r ;
  • R 12 is R', -C(O)R', -C(O)NR' 2 , -C(O)OR 15 , -S(O) m R' or S(O) m NR' 2 ;
  • R 13 is R', -CF3, -SR', or -OR';
  • R 14 is R', C(0)R', CN, NO 2 , SO 2 R' or C(O)OR 15 ;
  • R 15 is H, Ci-6alkyl or Ar-C ⁇ -4alkyl
  • D is H, C3-6cycloalkyl, Het or Ar
  • R' is H, Ci-6alkyl, Ar-C ⁇ -6alkyl or C3_6cycloalkyl-C ⁇ -6alkyl;
  • R" is R -C(O)R' or -C(O)OR';
  • R'" is H, C ⁇ alkyl, Ar-Co-6alkyl, Het-C ⁇ - ⁇ alkyl, or C3-6cycloalkyl-C()- 6 alkyl, halogen, CF 3 , OR f , S(O) k R f , COR f , NO 2 , N(Rf) 2 , CO(NR f ) 2 , CH 2 N(Rf) 2 ; n is 0 to 3; q is 0 to 3; t is 0 to 2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1 ; and v is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
  • this invention comprises formula (I) compounds of formula (la):
  • Y is C(O), C(S) or CH 2 ;
  • R 1 is R 7 , or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl, D-C3-4oxoalkenyl, D-C3_4oxoalkynyl, D-Cj_4aminoalkyl, D-C3_4aminoalkenyl, D-C3_4aminoalkynyl, optionally substituted by any accessible combination of one or more of R 1 * or R 7 ;
  • R is -(CH 2 ) r CO2R 3 ;
  • R 3 is H, C ⁇ _ 6 alkyl or (CHR ⁇ -Ar;
  • W is -(CHRg)a-U- (CHRg)b-;
  • G is NR e , S or O;
  • Rg is H, Cj.galkyl, Het-Co_6alkyl, C3_7cycloalkyl-C()-6alkyl or Ar-Co-6alkyl;
  • R k is Rg, -C(O)R8, or -C(O)OR f ;
  • R 1 is is H, Cj.galkyl, Het-C()-6alkyl, C3-7cycloalkyl-Co-6alkyl, Ar-Co-6 a l k y k or Cj.galkyl substituted by one to three groups chosen from halogen, CN, NRg 2 , ORg, SRg, CO 2 Rg, and CON(Rg) 2 ;
  • R f is H, C ⁇ galkyl or Ar-C ⁇ alkyl
  • R e is H, C ⁇ _6alkyl, Ar-C ⁇ galkyl, Het-Ci.galkyl, C3-7cycloalkyl-C ⁇ _6alkyl, or (CH 2 ) k CO 2 Rg;
  • R b and R c are independently selected from H, Cj.galkyl, Ar-C )-6alkyl, Het-Co-6alkyl, or C3-6cycloalkyl-Co_6alkyl, halogen, CF 3 , OR f , S(O) k R , COR f , NO2, N(R f )2, CO(NR ) 2 , CH 2 N(R f ) 2 , or R b and R c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C ⁇ _4alkyl, OR f , S(O) k R f , COR f , CO 2 R f , OH, NO 2 , N(R f ) 2) CO(NR f ) 2 , and CH2N(Rf) 2 ; or methylenedioxy;
  • Ci-6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR", -NO 2 , -CF 3 , R'S(O) , -CO 2 Rg, -CORg or -CONRg 2 ;
  • R5 is W'-(CR'2) q -Z-(CR'RlO) r u'-(CR'2) s ;
  • Y is absent, S or O;
  • Z is (CH2)t, Het, Ar or C3-7cycloalkyl
  • R 7 is -COR 8 , -COCR'2R 9 , -C(S)R 8 , -S(O) m OR', -S(0) m NR'R", -PO(OR'), -PO(OR')2, -B(OR') 2 , -NO 2 and Tet;
  • R 8 is -OR', -NRTT, -NR'SO R', -NR'OR', -OCR' C(O)OR', -OCR' 2 OC(O)- R', -OCR' 2 C(O)NR'2 or CF3;
  • R 9 is -OR', -CN, -S(O) r R', S(O) m NR'2, -C(O)R' C(O)NR'2 or -CO2R';
  • R 10 is H, C i-4alkyl or -NRH";
  • R 1 1 is H, halo, -OR 12 , -CN, -NR'R 12 , -NO2, -CF3, CF3S(O) r , -CO2R',
  • R 12 is R', -C(O)R', -C(O)NR' 2 , -C(O)OR 15 , -S(O) m R' or S(O) m NR' 2 ;
  • R 13 is R', -CF3, -SR', or -OR';
  • R 14 is R', C(O)R', CN, NO2, SO2R' or C(O)OR 15 ;
  • R 15 is H, Ci-6alkyl or Ar-C ⁇ -4alkyl
  • D is H, C3-6cycloalkyl, Het or Ar;
  • R' is H, C ⁇ _6alkyl, Ar-C ⁇ -6alkyl or C3-6cycloalkyl-C()-6alkyl;
  • R" is R', -C(O)R' or -C(O)OR';
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo.
  • this invention includes each unique nonracemic compound which may be synthesized and resolved by conventional techniques.
  • compounds may have unsaturated carbon- carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
  • compounds may exist in tautomeric forms, such as
  • keto-enol tautomers such as - ⁇ " ⁇ - and -""" ⁇
  • tautomers of guanidine-type NR' NR' 2 groups such as R"R'N A NR'-X- and R"R'N A N-X-
  • each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or locked in one form by appropriate substitution with R ⁇
  • the meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.
  • the compounds of formula (I) inhibit the binding of vitronectin and other
  • RGD-containing peptides to the vitronectin ( ⁇ v ⁇ 3 ) receptor.
  • Inhibition of the vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis and osteoarthritis.
  • the compounds of the instant invention inhibit vitronectin receptors on a number of different types of cells, said compounds would be useful in-the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis, and cardiovascular diseases, such as atherosclerosis and restenosis.
  • the compounds of Formula (I) of the present invention may be useful for the treatment or prevention of other diseases including, but not limited to, thromboembolic disorders, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplant rejection, septic shock, eczema, contact dermatitis, inflammatory bowel disease, and other autoimmune diseases.
  • the compounds of the present invention may also be useful for wound healing.
  • the compounds of the present invention are useful for the treatment, including prevention, of angiogenic disorders.
  • the term angiogenic disorders as used herein includes conditions involving abnormal neovascularization.
  • angiogenisis will reduce the deleterious effects of the disease.
  • An example of such a disease target is diabetic retinopathy.
  • inhibition of angiogenisis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow and the establishment of solid tumor metastases.
  • the compounds of the present invention inhibit tumor tissue angiogenesis, thereby preventing tumor metastasis and tumor growth.
  • the inhibition of angiogenesis using the compounds of the present invention can ameliorate the symptoms of the disease, and, in some cases, can cure the disease.
  • a preferred therapeutic target for the compounds of the instant invention are eye diseases chacterized by neovascularization.
  • eye diseases include corneal neovascular disorders, such as corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.
  • Additional eye diseases also include age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.
  • the dual fibrinogen/vitronectin receptor antagonists of the present invention in the inhibition of platelet aggregation and smooth muscle cell migration following vascular injury from percutaneous transluminal coronary angioplasty (PTC A).
  • PTC A percutaneous transluminal coronary angioplasty
  • the instant compounds are useful in vascular remodeling.
  • Y is C(O).
  • X 1 is CH2
  • A is NR'.
  • R 1 is H, CH3, CH2CH3, CH2CF3, (CH2)i-2Phenyl, in which the phenyl group is unsubstituted or substituted by C ⁇ -4 alkoxy, C ⁇ -4 alkthio, CF3, OH, or halo.
  • Suitable substituents for R 5 when fibrinogen antagonist acitivity is desired are:
  • R"HNC( NH)NH-(CH 2 ) 3 (CHR 10 )-, and R"HN-(CH 2 ) 5 -, wherein E is N or CH, and R 20 is hydrogen, amino, mono or
  • R' is H or C ⁇ -4 alkyl and R" is H.
  • Particularly preferred of such groups for R 5 are:
  • R" is H
  • Preferred substituents for the group attached to W in R 4 when vitronectin binding activity is desired are:
  • R b and R c are joined to form a cyclohexyl, phenyl or pyridyl ring.
  • R', R" and Rg are each H and s is 0 or 1.
  • R 4 A particularly preferred of such groups for R 4 is:
  • fibrinogen antagonist activity will be favored by an intramolecular distance of about 16 intervening covalent bonds via the shortest path between the oxygen of the carbonyl moiety of the R 2 group attached to the seven- membered ring, and the basic nitrogen moiety of R ⁇ ; while vitronectin antagonist activity will be favored by about 14 intervening covalent bonds via the shortest path between the oxygen of the carbonyl moiety attached to the seven-membered ring, and the basic nitrogen moiety of R 4 .
  • C ⁇ -4 alkyl as applied herein is meant to include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl.
  • Ci ⁇ alkyl additionally includes pentyl, n- pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. Any C ⁇ alkyl or Ci ⁇ alkyl group may be optionally substituted by R 1 unless otherwise indicated.
  • Co- 4 alkyl and Co-6alkyl additionally indicates that no alkyl group need be present (e.g., that a covalent bond is present).
  • C -6 alkenyl as applied herein means an alkyl group of 2 to 6 carbons wherein a carbon-carbon single bond is replaced by a carbon-carbon double bond.
  • C 2 _ 6 alkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene. isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included. Any C 2-6 alkenyl group may be optionally substituted by R 1 ' unless otherwise indicated.
  • C _6 alkynyl means an alkyl group of 2 to 6 carbons wherein one carbon- carbon single bond is replaced by a carbon-carbon triple bond.
  • C 2-6 alkynyl includes acetylene, 1-propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of pentyne and hexyne. Any sp 3 carbon atom in the C 2 _ 6 alkynyl group may be optionally substituted by R 1 *.
  • 4 ⁇ xoalkyl refers to an alkyl group of up to four carbons wherein a CH group is replaced by a C(O), or carbonyl, group. Substituted formyl, acetyl, 1- propanal, 2-propanone, 3-propanal, 2-butanone, 3-butanone, 1- and 4-butanal groups are representative.
  • C ⁇ _ 6 ⁇ xoalkyl includes additionally the higher analogues and isomers of five and six carbons substituted by a carbonyl group.
  • C 3- 6 ⁇ xoalkenyl and C 3 .60xoalkynyl refers to a C 3 _6alkenyl or Cs ⁇ alkynyl group wherein a CH 2 group is replaced by C(O) group.
  • C 3 - 4 ⁇ xoalkenyl includes l-oxo-2-propenyl, 3-oxo-l- propenyl, 2-oxo-3-butenyl and the like.
  • a substituent on a Cj-6 alkyl, C 2- 6 alkenyl, C 2-6 alkynyl or C ⁇ _6 oxoalkyl group, such as R 11 may be on any carbon atom which results in a stable structure, and is available by conventional synthetic techniques.
  • D-Ci- 6 alkyl refers to a Cj. 6 alkyl group wherein in any position a carbon- hydrogen bond is replaced by a carbon-D bond.
  • D-C 2-6 alkenyl and D-C 2- 6 alkynyl have a similar meaning with respect to C 2- 6 alkenyl and C 2- 6 alkynyl.
  • Ar, or aryl as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three moieties R
  • R 1 J may be Ci-4alkyl, C1.4aU.oxy, CF3, OH, or halo
  • Het, or heterocycle indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicychc ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur, which are stable and available by conventional chemical synthesis
  • Illustrative heterocycles are benzofuran, benzimidazole, benzopyran, benzothiophene, furan, lmidazole indole, indoline, morphohne, pipe ⁇ dine, p ⁇ erazine, pyrrole, pyrrohdine, tetrahydropyndine, py ⁇ dine, thiazole, thiophene, quinoline, isoquinoline, and tetra- and perhydro- quinoline and isoquinoline
  • C3-7cycloalkyl refers to an optionally substituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon-carbon bonds
  • Typical of C3 7cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cycloheptyl Any combination of up to three substituents, such as chosen from R 1 !, on the cycloalkyl ring that is available by conventional chemical synthesis and is stable, is within the scope of this invention
  • - indicates a nitrogen heterocycle which may be a saturated or unsaturated stable five-, six- or seven-membeied monocyclic ring, or a seven- to ten-membeied bicychc ring containing up to three nitrogen atoms or containing one nitrogen atom and a heteroatom chosen from oxygen and sulfur, and which may be substituted on any atom that results in a stable structure
  • the nitrogen atom in such ring may be substituted so as to result in a quaternary nitrogen
  • the nitrogen heterocycle may be substituted in any stable position by R 21 , for instance H, C alkoxy, F, Cl, Br, I, NO 2 , NR' 2 , OH, CO 2 R', CONHR', CF 3 , D-C 0-4 alkyl, D-Ci-4alkyl-S(O) u (e g , where u is 0, 1 or 2) or Ci ⁇ alkyl substituted by any of the
  • aforementioned sustituents Representative of — ' are pyrrohne, pyrrohdine, lmidazole, lmidazohne, lmidazohdine, pyrazole, pyrazo ne, pyrazohdine, pipe ⁇ dine, piperazine, morphohne, py ⁇ dine, py ⁇ dinium, tetrahydropyndine, tetrahydro- and hexahydro-azepine, quinuchdine, quinuc dinium, quinoline, or tetrahydropyridinyl.
  • v ⁇ --) is preferably 4-pyridyl, 4-(2-amino-pyridyl), 4- tetrahydropyridyl, 4-piperidinyl or 4-piperazinyl.
  • R b and R c are joined together to form a five- or six-membered aromatic or non-aromatic ring fused to the ring to which R b and R c are attached, the ring formed will generally be a five- or six-membered heterocycle selected from those listed above for Het, or will be a phenyl, cyclohexyl or cyclopentyl ring.
  • Benzimidazolyl, 4-azabenzimidazolyl, 5-azabenzimidazolyl and substituted derivatives thereof are prefe ⁇ ed moieties for the group attached to W in R 4 .
  • t-Bu refers to the tertiary butyl radical
  • Boc refers to the t-butyloxycarbonyl radical
  • Fmoc refers to the fluorenylmethoxycarbonyl radical
  • Ph refers to the phenyl radical
  • Cbz refers to the benzyloxycarbonyl radical
  • BrZ refers to the o-bromobenzyloxycarbonyl radical
  • CIZ refers to the o-chlorobenzyloxycarbonyl radical
  • Bn refers to the benzyl radical
  • 4-MBzl refers to the 4-methyl benzyl radical
  • Me refers to methyl
  • Et refers to ethyl
  • Ac refers to acetyl
  • Alk refers to Cj ⁇ alkyl
  • Nph refers to 1- or 2-naphthyl
  • cHex refers to cyclohexyl.
  • MeArg is N ⁇ -methyl arginine. Tet refers to 5-tetrazolyl. Certain reagents are abbreviated herein.
  • DCC refers to dicyclohexylcarbodiimide
  • DMAP refers to dimethvlaminopyridine
  • DIEA diisopropylethylamine
  • EDC N-ethyl-N'(dimethylaminopropyl)- carbodiimide.
  • HOBt refers to 1-hydroxybenzotriazole
  • THF refers to tetrahydrofuran
  • DMF refers to dimethyl formamide
  • NBS refers to N-bromo- succinimide
  • Pd/C refers to a palladium on carbon catalyst.
  • DPPA diphenylphosphoryl azide
  • BOP refers to benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate
  • HF hydrofluoric acid
  • PPA refers to polyphosphoric acid
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • PCC pyridinium chlorochromate
  • a suitably protected benzazepine or benzodiazepine such as II-l (prepared as described in Bondinell, et al., PCT application WO 93/00095, published January 7, 1993 and Bondinell, et al., PCT application WO 94/14776, published July 7, 1994) is converted to an activated form using, for example, EDC and HOBt, and the activated form is subsequently reacted with a suitably protected arginine mimic, such as 1-5 (prepared as above), in a suitable solvent such as DMF or C ⁇ C ⁇ - Depending on whether acid nuetralization is required, an added base, such as diisopropylethylamine, may be used.
  • a suitably protected benzazepine or benzodiazepine such as II-l (prepared as described in Bondinell, et al., PCT application WO 93/00095, published January 7, 1993 and Bondinell, et al., PCT application WO 94/14776
  • the methyl ester of II-2 is hydrolyzed with aqueous base, such as, NaOH in aqueous MeOH and the t-butyl carbamate is removed with a strong acid, such as TFA in CH2CI2 or HCl in dioxane.
  • a strong acid such as TFA in CH2CI2 or HCl in dioxane.
  • the intermediate carboxylate salt is acidified with a suitable acid, such as TFA or HCl to afford the carboxylic acid II-3.
  • the tricyclic core of the compounds of formula (II) are prepared as described in Bondinell, et al., PCT Application WO 97/01540, published January 16, 1997. Reference should be made to said patent application, the entire disclosure of which is incorporated by reference.
  • the formula (II) compounds are prepared by methods analogous to those detailed in Scheme II. Coupling methods to form amide bonds are generally well known to the art. The methods of peptide synthesis generally set forth by Bodansky et al., THE PRACTICE OF PEPTIDE SYNTHESIS, Springer- Verlag, Berlin, 1984, Ali et al. in /. Med. Chem., 29, 984 (1986) and J. Med.
  • Coupling reagents as used herein denote reagents which may be used to form amide bonds.
  • Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides.
  • Reagents such as EDC, DCC, DPPA, BOP reagent, HOBt, N- hydroxysuccinimide and oxalyl chloride are typical.
  • the amine or aniline is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as N,N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine (DMAP).
  • a suitable carbodiimide coupling agent such as N,N' dicyclohexyl carbodiimide (DCC)
  • catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine (DMAP).
  • HABt 1-hydroxybenzotriazole
  • DMAP dimethylamino pyridine
  • Other methods such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine of a suitably protected amine, optionally in the presence of a base, are also suitable.
  • Boc-amino acid or Cbz-amidino benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran(THF), in the pre sence of a base, such as N-methyl mo ⁇ holine, DMAP or a trialkylamine, with isobutyl chloroformate to form the
  • activated anhydride which is subsequently reacted with the free amine of a second protected amino acid or aniline.
  • Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hvdrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic. succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable.
  • Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li + , Na+, K+, Ca ++ , Mg ++ and NH4+ are specific examples of cations present in pharmaceutically acceptable salts.
  • compositions of the compounds of formula (I) may be used in the manufacture of a medicament.
  • Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpynolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • excipients such as polyvinylpynolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • Liquid carriers include syrup, peanut oil, olive oil, saline and water.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • the compounds described herein which are antagonists of the vitronectin receptor are useful for treating diseases wherein the underlying pathology is attributable to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology.
  • the instant compounds are useful for the treatment of ostoeporosis, hype ⁇ arathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency.
  • the compounds of this invention are also believed to have utility as antitumor, antiinflammatory, anti-angiogenic and anti-metastatic agents, and be useful in the treatment of cancer, atherosclerosis and restenosis.
  • the compounds of this invention are useful for inhibiting restenosis following angioplasty.
  • the compounds of this invention which inhibit fibrinogen binding provide a method of inhibiting platelet aggregation and clot formation in a mammal, especially a human, which comprises the internal administration of a compound of formula (I) and a pharmaceutically acceptable carrier.
  • Indications for such therapy include acute myocardial infarction (AMI), deep vein thrombosis, pulmonary embolism, dissecting anurysm, transient ischemia attack (TIA), stroke and other infarct-related disorders, and unstable angina.
  • DIC disseminated intravascular coagulation
  • septicemia surgical or infectious shock
  • post-operative and post-partum trauma cardiopulmonary bypass surgery
  • incompatible blood transfusion abruptio placenta
  • thrombotic thrombocytopenic pu ⁇ ura TTP
  • snake venom and immune diseases
  • the compounds of this invention may be useful in a method for the prevention of metastatic conditions, the prevention or treatment of fungal or bacterial infection, inducing immunostimulation, treatment of sickle cell disease, and the prevention or treatment of diseases in which bone reso ⁇ tion is a factor.
  • This invention further provides a method for inhibiting the reocclusion of an artery or vein following fibrinolytic therapy, which comprises internal administration of a compound of formula (I) and a fibrinolytic agent.
  • Administration of a compound of formula (I) in fibrinolytic therapy either prevents reocclusion completely or prolongs the time to reocclusion.
  • fibrinolytic agent is intended to mean any compound, whether a natural or synthetic product, which directly or indirectly causes the lysis of a fibrin clot.
  • Plasminogen activators are a well known group of fibrinolytic agents.
  • Useful plasminogen activators include, for example, anistreplase, urokinase (UK), pro-urokinase (pUK), streptokinase (SK), tissue plasminogen activator (tPA) and mutants, or variants, thereof.
  • the compounds of this invention may also be used in vitro to inhibit the aggregation of platelets in blood and blood products, e.g., for storage, or for ex vivo manipulations such as in diagnostic or research use.
  • the compound is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone reso ⁇ tion, or inhibit platelet aggregation or other such indication.
  • the pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg.
  • parenteral administration is preferred.
  • An intravenous infusion of the compound in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful.
  • the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg.
  • the compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day.
  • the precise level and method by which the compounds are administered is readily determined by one routinely skilled in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • the compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
  • the wells were washed once with buffer A and were incubated with 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
  • the IC 50 concentration of the antagonist to inhibit 50% binding of [ 3 H]-SK&F- 107260
  • the Kj dissociation constant of the antagonist
  • c i b ⁇ 3 was diluted to a final concentration of 0.5 mg/mL and mixed with the phospholipids in a protein:phospholipid ratio of 1 :3 (w:w). The mixture was resuspended and sonicated in a bath sonicator for 5 min. The mixture was then dialyzed overnight using 12,000-14,000 molecular weight cutoff dialysis tubing against a 1000-fold excess of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaC12 (with 2 changes).
  • ⁇ b ⁇ 3 -containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70°C until needed.
  • the binding to the fibrinogen receptor ( ⁇ b ⁇ 3) was assayed by an indirect competitive binding method using [ 3 H]-SK&F- 107260 as an RGD-type ligand.
  • the binding assay was performed in a 96-well filtration plate assembly (Millipore Co ⁇ oration, Bedford, MA) using 0.22 um hydrophilic durapore membranes.
  • the wells were precoated with 0.2 mL of 10 ⁇ g/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding.
  • Various concentrations of unlabeled benzadiazapines were added to the wells in quadruplicate.
  • [ 3 H]-SK&F- 107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 ⁇ g of the purified platelet ⁇ b ⁇ 3-containing liposomes. The mixtures were incubated for 1 h at room temperature. The 0t ⁇ ⁇ 3- bound [3HJ-SK&F- 107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL). Bound radioactivity remaining on the filters was counted in 1.5 mL Ready Solve (Beckman Instruments, Fullerton, CA) in a Beckman Liquid
  • Inhibition of platelet aggregation may be measured by the method described in WO 93/00095 (PCT/US/92/05463).
  • In vivo thrombus formation is demonstrated by recording the systemic and hemodynamic effects of infusion of the peptides into anesthetized dogs according to the methods described in Aiken et al., Prostaglandins, 19, 620 (1980).
  • the compounds of the instant invention were tested for their ability to inhibit the migration and proliferation of smooth muscle tissue in an artery or vein in order to assess their ability to prevent restenosis of an artery, such as that which typically occurs following angioplasty.
  • Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane with pores of 8 um (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 10 6 cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin.
  • Incubation was carried out at 37°C in an atmosphere of 95% air/5% CO 2 for 24 hr. After incubation, the non-migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured either by a) counting the number of cells that had migrated to the lower surface of the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
  • the efficacy of the compounds of formula (I) to prevent tumor growth may be determined using several transplantable mouse tumor models. See U. S. Patent Nos. 5,004,758 and 5,633,016 for details of these models.
  • Nuclear magnetic resonance spectra were obtained using either a Bruker AM 250 or Bruker AC 400 spectrometer. Chemical shifts are reported in parts per milliom ( ⁇ ) downfield from the internal standard tetramethylsilane. Mass spectra were taken on either VG 70 FE or VG ZAB HF instruments using fast atom bombardment (FAB) or electrospry-(ES) ionization techniques. Elemental analyses were performed by Quantitative Technologies Inc., Whitehouse, New Jersey.
  • (+/-)-2,3,4,5-tetrahydro-3-oxo-8- [[/V-(4-N-f-butoxycarbonylpiperidinylpropyl-/V-( 1 H-benzimidazol-2- ylmethyl)]aminocarbonyl]-2-methyl-lH-2-benzazepine-4-acetic acid, methyl ester (0.19 g, 0.29 mmol) gave 0.23 g of the desired product as a white foam after reverse phase flash chromatography (step gradient: H2O + 0.1% TFA then 30% CH3CN/H2O + 0.1% TFA, Analytichem Bond-Elut® C-8 column, 50 mL size).
  • a tablet for oral administration is prepared by mixing and granulating 20 mg of sucrose, 150 mg of calcium sulfate dihydrate and 50 mg of the compound of Example 1 with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with 10 mg starch, 5 mg talc and 3 mg stearic acid; and compressed into a tablet.

Abstract

Compounds of the formula (I) are disclosed which are dual fibrinogen receptor and vitronectin receptor antagonists and are useful in the treatment of atherosclerosis, in the prevention of restenosis and in the prevention of tumor metastasis and tumor growth.

Description

TITLE
Integrin Receptor Antagonists
FIELD OF THE INVENTION
This invention relates to pharmaceutically active compounds which bind to integrins, such as dual antagonists of the vitronectin receptor and the fibrinogen receptor. Such compounds are useful for inhibiting platelet aggregation, treating restenosis and atherosclerosis and are useful in vascular remodeling.
BACKGROUND OF THE INVENTION
Integrins are a family of heterodimeric proteins which generally mediate cell adhesion. Typical of such proteins are the vitronectin receptor (an αγβ3 heterodimer) and the fibrinogen receptor (an απbβ3 heterodimer). The natural ligands of these receptors (e.g., vitronectin and fibrinogen) have been found to share a common -Arg-Gly-Asp- amino acid sequence, which appears to be critical for binding. In fact, many of the integrin receptors appear to cross react with ligands which possess such an amino acid sequence. For instance, the αnbβ3 receptor reacts with fibronectin and vitronectin, thrombospondin and von Willebrand factor, as well as fibrinogen. Functionally fibrinogen, a dimer having two binding sites for απbβ3, reacts with activated receptors found on the surface of platelets. The binding of 0Cπbβ3 receptors on adjacent platelets, by fibrinogen leads to crosslinking and is considered to be a major factor in platelet aggregation. Compounds which inhibit the binding of the απbβ3 receptor to fibrinogen have been shown to inhibit the platelet aggregation in vitro, and thrombus formation in vivo. See, for instance, EP- A 0 341 915. Animal models have demonstrated that inhibition of the απbβ3 receptor may reduce neointimal hyperplasia after angioplasty. Friedman, et al., J. Clin. Invest., 1977, 60, 1191. Additionally, studies have shown that απbβ3 antagonists have been able to prevent tumor invasion and metastasis in vitro. Honn, et al., Cancer Res., 1997, 57, 2522.
The vitronectin receptor otyββ is expressed on a number of cells, including endothelial, smooth muscle, osteoclast, and tumor cells, and, thus, it has a variety of functions. It has been reported that the αvB3 receptor expressed on human aortic smooth muscle cells stimulates their migration into neointima, which leads to the formation of atherosclerosis and restenosis after angioplasty. Brown, et al., Cardiovascular Res., 1994, 28, 1815. Additionally, a study has shown that a αyββ antagonist is able to promote tumor regression by inducing apoptosis of angiogenic blood vessels. Brooks, et al., Cell, 1994, 79, 1157. Thus, agents that block the vitronectin receptor and the fibrinogen receptor would be useful in treating diseases mediated by these receptors, such as atherosclerosis, restenosis (Topol. et al., J. Am. Coll. Cardiol, 1996, 28, 1643.) and cancer.
It has now been discovered that certain new compounds are useful as integrin receptor antagonists, in particular the compounds of the present invention are useful as dual απbβ3/o:vβ3 receptor antagonists.
SUMMARY OF THE INVENTION
It is an object of this invention to provide compounds of the formula (I), as described hereinafter, which have pharmacological activity for the inhibition of integrin receptors. It is an object of this invention to provide a template which may be suitably substituted to provide selective binding for specific integrin receptors, especially the fibrinogen (αιibβ3) and the vitronectin (αγβ3) receptors relative to each other and other integrin receptors.
This invention is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically carrier.
This invention is also a method of treating diseases in which the pathology may be modified by binding to integrin receptors, especially the vitronectin and the fibrinogen receptors. In a particular aspect, the compounds of this invention are useful for treating atherosclerosis and restenosis, and conditions in which it is desirable to inhibit platelet aggregation, such as stroke, transient ischemia attacks, myocardial infarction and rethrombosis following thrombolytic therapy.
DETAILED DESCRIPTION
This invention comprises compounds of formulae (I) or (II):
Figure imgf000004_0001
wherein:
A is NR', CHR', O or S;
A, is C or N; χl and X^ are C=O or CHR', with the proviso that only one of X1 or X^ is
C=O;
Figure imgf000005_0001
-membered heteroaromatic or six-membered aromatic ring optionally substituted by R11 ;
Figure imgf000005_0002
EisO, S,C(O)orC(S);
YisC(O), C(S)orCH2; R1 is R7, or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl,
D-C3-4oxoalkenyl, D-C3-4oxoalkynyl, D-Ci^aminoalkyl, D-C3_4aminoalkenyl, D-C3_4aminoalkynyl, optionally substituted by any accessible combination of one or more of R11 or R7;
R2 is -(CH2)t-CO R3; R3isH, Ci_6alkylor(CHRVAr;
R4is
-
Figure imgf000005_0003
Figure imgf000006_0001
W is -(CHRg)a-U- (CHRg)b-;
U is absent or CO, CRg , C(=CRg2), S(0)k, O, NRg, CRgORg, CRg(ORk)CRg , CRg2CRg(ORk), C(O)CRg , CRg2C(O), CONR1, NR1 CO, OC(O), C(O 0, C(S)O, OC(S), C(S)NRg, NRgC(S), S(0)2NRg, NRgSfO)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg2O, OCRg2, C ≡C or CRg=CRg; G is NRe, S or O;
Rg is H, C j^alkyl, Het-C()-6alkyl, C3-7cycloalkyl-C _6alkyl or Ar-CQ-6alkyl;
Rk is Rg, -C(O)Rg, or -C(O)ORf;
Ri is is H, C j .galkyl, Het-Cø-όalkyl, C3-7cycloalkyl-Co-6alkyl, Ar-Co-6alkyl, or C j.galkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2; Rf is H, C ι_6alkyl or Ar-Cj.galkyl;
Re is H, Ci.galkyl, Ar-C^galkyl, Het-C ^galkyl. Cs- cycloalkyl-C galkyl,
Figure imgf000006_0002
Rb and Rc are independently selected from H, C j.galkyl, Ar-Co-ζalkyl,
Het-Co-6alkyl, or C3-6cycloalkyl-Co_6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, Cι_4alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, N0 , N(Rf)2, CO(NRf)2, and CH2N(Rf)2; or methylenedioxy;
Q . Q^» Q3 nd Q^ are independently N or C-RY, provided that no more than one of QΛ Q2, Q3 and Q4 is N;
RY is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, CF3S(O)r, -CO2Rg, -CORg or -CONRg2, or C 1 _6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR", -NO2, -CF3, R'S(O)r, -CO2Rg, -CORg or -CONRg2; R5 is W'-(CR,2)q-Z-(CR'RlO)r-U'-(CR'2)s;
U' is absent or CO, CR'2, C(=CR'2), S(O)n, O, NR', CR'OR", CR'(OR")CR'2,
CR'2CR'(OR"), C(O)CR'2, CR'2C(O), CONR, NR'CO, OC(O), C(O)O, C(S)O,
OC(S), C(S)NR', NR'C(S), S(O)nNR', NR'S(O)n, N=N, NR'NR', NR'CR'2, NR'CR'2, CR'2O, OCR'2, c≡ c or CR'=CR;
Figure imgf000007_0001
is N=CR', C(O) or O; Y is absent, S or O;
Z is (CH2)t, Het. Ar or C3-7cycloalkyl;
R7 is -COR8, -COCR'2R9, -C(S)R8, -S(0)mOR,, -S(0)mNR'R", -PO(OR'), -PO(OR')2, ^(OR^, -N02 and Tet;
R8 is -OR', -NRR", -NR'SO2R', -NR'OR', -OCR'2C(O)OR', -OCR'2OC(O)- R', -OCR'2C(O)NR'2 or CF3;
R9 is -OR', -CN, -S(O)rR', S(O)mNR'2, -C(O)R' C(O)NR'2 or -CO2R';
R10 is H, C alkyl or -NRR"; each Ru independently is H, halo, -OR12, -CN, -NR'R12, -NO2, -CF3, CF3S(O)r, -CO2R', -CONR'2, D-Cθ-6alkyl-, D-Cι_6oxoalkyl-, D-C2-6alkenyl-, D-C2-6alkynyl-, D-Cθ-6alkyloxy-, D-Cθ-6alkylamino- or D-Cθ-6alkyl-S(O)r;
R12 is R', -C(O)R', -C(O)NR'2, -C(O)OR15, -S(O)mR' or S(O)mNR'2;
R13 is R', -CF3, -SR', or -OR';
R 14 is R', C(0)R', CN, NO2, SO2R' or C(O)OR 15;
R15 is H, Ci-6alkyl or Ar-Cθ-4alkyl; D is H, C3-6cycloalkyl, Het or Ar;
R' is H, Ci-6alkyl, Ar-Cθ-6alkyl or C3_6cycloalkyl-Cθ-6alkyl;
R" is R -C(O)R' or -C(O)OR';
R'" is H, C ^alkyl, Ar-Co-6alkyl, Het-Cø-όalkyl, or C3-6cycloalkyl-C()- 6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2; n is 0 to 3; q is 0 to 3; t is 0 to 2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1 ; and v is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
Preferably, this invention comprises formula (I) compounds of formula (la):
Figure imgf000008_0001
wherein:
A is NR', CHR', O or S; χl and X2 are C=O or CHR', with the proviso that only one of X1 or X2 is
C=O;
Y is C(O), C(S) or CH2;
R1 is R7, or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl, D-C3-4oxoalkenyl, D-C3_4oxoalkynyl, D-Cj_4aminoalkyl, D-C3_4aminoalkenyl, D-C3_4aminoalkynyl, optionally substituted by any accessible combination of one or more of R1 * or R7;
R is -(CH2)rCO2R3;
R3 is H, Cι_6alkyl or (CHR^-Ar;
Figure imgf000008_0002
Figure imgf000009_0001
W is -(CHRg)a-U- (CHRg)b-;
U is absent or CO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(0), CONRi, NR1 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(0)2NRg, NRgS(0)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg O, OCRg , C≡C or CRg=CRg;
G is NRe, S or O;
Rg is H, Cj.galkyl, Het-Co_6alkyl, C3_7cycloalkyl-C()-6alkyl or Ar-Co-6alkyl; Rk is Rg, -C(O)R8, or -C(O)ORf;
R1 is is H, Cj.galkyl, Het-C()-6alkyl, C3-7cycloalkyl-Co-6alkyl, Ar-Co-6alkyk or Cj.galkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2;
Rf is H, C^galkyl or Ar-C^alkyl; Re is H, Cι_6alkyl, Ar-C^galkyl, Het-Ci.galkyl, C3-7cycloalkyl-Cι_6alkyl, or (CH2)kCO2Rg;
Rb and Rc are independently selected from H, Cj.galkyl, Ar-C )-6alkyl, Het-Co-6alkyl, or C3-6cycloalkyl-Co_6alkyl, halogen, CF3, ORf, S(O)kR , CORf, NO2, N(Rf)2, CO(NR )2, CH2N(Rf)2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, Cι _4alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2) CO(NRf)2, and CH2N(Rf)2; or methylenedioxy; θΛ Q2 > Q3 and Q4 are independently N or C-RY, provided that no more than one of QΛ Q2, Q3 and Q4 is N; RY is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF , CF3S(O)r, -CO2Rg,
-CORg or -CONRg2, or Ci-6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR", -NO2, -CF3, R'S(O) , -CO2Rg, -CORg or -CONRg2;
R5 is W'-(CR'2)q-Z-(CR'RlO)ru'-(CR'2)s;
U' is absent or CO, CR'2, C(=CR2), S(O)n, O, NR', CR'OR', CR'(OR")CR'2, CR'2CR'(OR"), C(O)CR'2, CR'2C(O), CONR', NR'CO, OC(O), C(O)O, C(S)O,
OC(S), C(S)NR', NR'C(S), S(O)nNR , NR S(O)n, N=N, NR'NR', NR'CR'2,
NR'CR'2, CR'2θ, OCR'2, c≡ c or CR'=CR';
Figure imgf000010_0001
is N=CR', C(O) or O;
Y is absent, S or O;
Z is (CH2)t, Het, Ar or C3-7cycloalkyl;
R7 is -COR8, -COCR'2R9, -C(S)R8, -S(O)mOR', -S(0)mNR'R", -PO(OR'), -PO(OR')2, -B(OR')2, -NO2 and Tet;
R8 is -OR', -NRTT, -NR'SO R', -NR'OR', -OCR' C(O)OR', -OCR'2OC(O)- R', -OCR'2C(O)NR'2 or CF3;
R9 is -OR', -CN, -S(O)rR', S(O)mNR'2, -C(O)R' C(O)NR'2 or -CO2R';
R10 is H, C i-4alkyl or -NRH"; R1 1 is H, halo, -OR12, -CN, -NR'R12, -NO2, -CF3, CF3S(O)r, -CO2R',
-CONR'2, D-Co-6alkyl-, D-C i-6oxoalkyl-, D-C2-6alkenyl-, D-C2-6alkynyl-, D-Cθ-6alkyloxy-, D-Cθ-6alkylamino- or D-Cθ-6alkyl-S(O)r;
R12 is R', -C(O)R', -C(O)NR'2, -C(O)OR15, -S(O)mR' or S(O)mNR'2;
R13 is R', -CF3, -SR', or -OR'; R14 is R', C(O)R', CN, NO2, SO2R' or C(O)OR15;
R15 is H, Ci-6alkyl or Ar-Cθ-4alkyl;
D is H, C3-6cycloalkyl, Het or Ar;
R' is H, Cι_6alkyl, Ar-Cθ-6alkyl or C3-6cycloalkyl-C()-6alkyl;
R" is R', -C(O)R' or -C(O)OR'; R'" is H, .galkyl, Ar-Co-ealkyl, Het-Co-6alkyl, or C3_6cycloalkyl-Cθ- 6alkyl, halogen, CF , ORf, S(O)kRf, COR , NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2; n is 0 to 3; q is 0 to 3; t is 0 to 2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1 ; and v is 0 or 1 ; or a pharmaceutically acceptable salt thereof. Also included in this invention are pharmaceutically acceptable addition salts, complexes or prodrugs of the compounds of this invention. Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo. In cases wherein the compounds of this invention may have one or more chiral centers, unless specified, this invention includes each unique nonracemic compound which may be synthesized and resolved by conventional techniques. In cases in which compounds have unsaturated carbon- carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. In cases wherein compounds may exist in tautomeric forms, such as
O OR' keto-enol tautomers, such as -^"~~- and -"""^^ , and tautomers of guanidine-type NR' NR'2 groups, such as R"R'N A NR'-X- and R"R'N A N-X- , each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or locked in one form by appropriate substitution with R\ The meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise. The compounds of formula (I) inhibit the binding of vitronectin and other
RGD-containing peptides to the vitronectin (αvβ3) receptor. Inhibition of the vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis and osteoarthritis. Additionally, since the compounds of the instant invention inhibit vitronectin receptors on a number of different types of cells, said compounds would be useful in-the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis, and cardiovascular diseases, such as atherosclerosis and restenosis. The compounds of Formula (I) of the present invention may be useful for the treatment or prevention of other diseases including, but not limited to, thromboembolic disorders, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplant rejection, septic shock, eczema, contact dermatitis, inflammatory bowel disease, and other autoimmune diseases. The compounds of the present invention may also be useful for wound healing. In particular, the compounds of the present invention are useful for the treatment, including prevention, of angiogenic disorders. The term angiogenic disorders as used herein includes conditions involving abnormal neovascularization. Where the growth of new blood vessels is the cause of, or contributes to, the pathology associated with a disease, inhibition of angiogenisis will reduce the deleterious effects of the disease. An example of such a disease target is diabetic retinopathy. Where the growth of new blood vessels is required to support growth of a deleterious tissue, inhibition of angiogenisis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow and the establishment of solid tumor metastases. Thus, the compounds of the present invention inhibit tumor tissue angiogenesis, thereby preventing tumor metastasis and tumor growth.
Thus, according to the methods of the present invention, the inhibition of angiogenesis using the compounds of the present invention can ameliorate the symptoms of the disease, and, in some cases, can cure the disease.
A preferred therapeutic target for the compounds of the instant invention are eye diseases chacterized by neovascularization. Such eye diseases include corneal neovascular disorders, such as corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use. Additional eye diseases also include age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.
In another aspect of the invention is the use of the dual fibrinogen/vitronectin receptor antagonists of the present invention in the inhibition of platelet aggregation and smooth muscle cell migration following vascular injury from percutaneous transluminal coronary angioplasty (PTC A). The instant compounds are useful in vascular remodeling.
With reference to formula (la), preferably, Y is C(O). With reference to formula (la), suitably, X1 is CH2, X2 is C=O and A is NR'.
Preferably, with reference to formula (la):
X1 is CH2, X2 is C=O, A is NR', R' is H or Cι_4alkyl, Y is C(O), R1 is D-C )-4alkyl, optionally substituted by R11, and R2 is -CH2-CO2H. In particular, R1 is H, CH3, CH2CH3, CH2CF3, (CH2)i-2Phenyl, in which the phenyl group is unsubstituted or substituted by
Figure imgf000013_0001
Cι-4alkoxy, Cι-4alkthio, CF3, OH, or halo.
Suitable substituents for R5 when fibrinogen antagonist acitivity is desired are:
Figure imgf000013_0002
Figure imgf000013_0003
R"HNC(=NH)NH-(CH2)3(CHR10)-, and R"HN-(CH2)5-, wherein E is N or CH, and R20 is hydrogen, amino, mono or
Figure imgf000013_0004
Particularly good substituents for promoting fibrinogen antagonist activity are:
Figure imgf000013_0005
Figure imgf000014_0001
wherein R' is H or Cι-4alkyl and R" is H. Particularly preferred of such groups for R5 are:
Figure imgf000014_0002
wherein R" is H.
Preferred substituents for the group attached to W in R4 when vitronectin binding activity is desired are:
Figure imgf000014_0003
/> and wherein G is NH. Prefe ύrably, Rb and Rc are joined to form a cyclohexyl, phenyl or pyridyl ring. Suitably, R', R" and Rg are each H and s is 0 or 1.
Specific preferred R4 substituents for enhancing vitronectin activity are
Figure imgf000014_0004
Figure imgf000015_0001
A particularly preferred of such groups for R4 is:
Figure imgf000015_0002
By appropriate selection of the spacing of the substituents R4 and R^ from the phenyl ring of the 6-7 ring system, compounds having selective activity for both the vitronectin and fibrinogen receptors, i.e. dual activity for both receptors, may be obtained. In general, fibrinogen antagonist activity will be favored by an intramolecular distance of about 16 intervening covalent bonds via the shortest path between the oxygen of the carbonyl moiety of the R2 group attached to the seven- membered ring, and the basic nitrogen moiety of R^; while vitronectin antagonist activity will be favored by about 14 intervening covalent bonds via the shortest path between the oxygen of the carbonyl moiety attached to the seven-membered ring, and the basic nitrogen moiety of R4.
Specific compounds of this invention are: (S)-7-[[jV-(4-pyridinylpropyl)-N-(lH-benzimidazol-2-ylmethyl)]- aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid;
(S)-7-[[N-4-piperidinylpropyl-N-(lH-benzimidazol-2-ylmethyl)]- aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo- 1H- 1 ,4-benzodiazepine-2-acetic acid;
(S)-7-[[N-4-piperidinylethyl-N-(lH-benzimidazol-2-ylmethyl)]- aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid; and (+/-)-2,3,4,5-tetrahydro-3-oxo-8-[[N-4-piperidinylpropyl-iV-(lH- benzimidazol-2-ylmethyl)]aminocarbonyl]-2-methyl-lH-2-benzazepine-4-acetic acid; or a pharmaceutically acceptable salt thereof. Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of this invention.
Cι-4alkyl as applied herein is meant to include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl. Ci^alkyl additionally includes pentyl, n- pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. Any C^alkyl or Ci^alkyl group may be optionally substituted by R1 unless otherwise indicated. Co-4alkyl and Co-6alkyl additionally indicates that no alkyl group need be present (e.g., that a covalent bond is present).
C -6 alkenyl as applied herein means an alkyl group of 2 to 6 carbons wherein a carbon-carbon single bond is replaced by a carbon-carbon double bond. C2_6alkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene. isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included. Any C2-6alkenyl group may be optionally substituted by R1 ' unless otherwise indicated.
C _6 alkynyl means an alkyl group of 2 to 6 carbons wherein one carbon- carbon single bond is replaced by a carbon-carbon triple bond. C2-6 alkynyl includes acetylene, 1-propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of pentyne and hexyne. Any sp3 carbon atom in the C2_6alkynyl group may be optionally substituted by R1 *.
C].4θxoalkyl refers to an alkyl group of up to four carbons wherein a CH group is replaced by a C(O), or carbonyl, group. Substituted formyl, acetyl, 1- propanal, 2-propanone, 3-propanal, 2-butanone, 3-butanone, 1- and 4-butanal groups are representative. Cι_6θxoalkyl includes additionally the higher analogues and isomers of five and six carbons substituted by a carbonyl group. C3-6θxoalkenyl and C3.60xoalkynyl refers to a C3_6alkenyl or Cs^alkynyl group wherein a CH2 group is replaced by C(O) group. C3-4θxoalkenyl includes l-oxo-2-propenyl, 3-oxo-l- propenyl, 2-oxo-3-butenyl and the like.
A substituent on a Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or Cι_6 oxoalkyl group, such as R11, may be on any carbon atom which results in a stable structure, and is available by conventional synthetic techniques. D-Ci-6 alkyl refers to a Cj.6 alkyl group wherein in any position a carbon- hydrogen bond is replaced by a carbon-D bond. D-C2-6 alkenyl and D-C2-6 alkynyl have a similar meaning with respect to C2-6 alkenyl and C2-6 alkynyl. Ar, or aryl, as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three moieties R In particular, R1 J may be Ci-4alkyl, C1.4aU.oxy,
Figure imgf000017_0001
CF3, OH, or halo
Het, or heterocycle, indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicychc ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur, which are stable and available by conventional chemical synthesis Illustrative heterocycles are benzofuran, benzimidazole, benzopyran, benzothiophene, furan, lmidazole indole, indoline, morphohne, pipeπdine, pφerazine, pyrrole, pyrrohdine, tetrahydropyndine, pyπdine, thiazole, thiophene, quinoline, isoquinoline, and tetra- and perhydro- quinoline and isoquinoline A six membered ring heterocycle containing one or two nitrogens, such as pipeπdine, piperazine, tetrahydropyndine and pyπdine, are preferred heterocycles for the moiety Z Any accessible combination of up to three substituents. such as chosen from R1 ' , on the Het ring that is available by chemical synthesis and is stable is within the scope of this invention
C3-7cycloalkyl refers to an optionally substituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon-carbon bonds Typical of C3 7cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cycloheptyl Any combination of up to three substituents, such as chosen from R1 !, on the cycloalkyl ring that is available by conventional chemical synthesis and is stable, is within the scope of this invention
- as used herein indicates a nitrogen heterocycle which may be a saturated or unsaturated stable five-, six- or seven-membeied monocyclic ring, or a seven- to ten-membeied bicychc ring containing up to three nitrogen atoms or containing one nitrogen atom and a heteroatom chosen from oxygen and sulfur, and which may be substituted on any atom that results in a stable structure The nitrogen atom in such ring may be substituted so as to result in a quaternary nitrogen The nitrogen heterocycle may be substituted in any stable position by R21, for instance H, C alkoxy, F, Cl, Br, I, NO2, NR'2, OH, CO2R', CONHR', CF3, D-C0-4alkyl, D-Ci-4alkyl-S(O)u (e g , where u is 0, 1 or 2) or Ci^alkyl substituted by any of the
aforementioned sustituents Representative of — ' are pyrrohne, pyrrohdine, lmidazole, lmidazohne, lmidazohdine, pyrazole, pyrazo ne, pyrazohdine, pipeπdine, piperazine, morphohne, pyπdine, pyπdinium, tetrahydropyndine, tetrahydro- and hexahydro-azepine, quinuchdine, quinuc dinium, quinoline,
Figure imgf000018_0001
or tetrahydropyridinyl. v^--) is preferably 4-pyridyl, 4-(2-amino-pyridyl), 4- tetrahydropyridyl, 4-piperidinyl or 4-piperazinyl. When Rb and Rc are joined together to form a five- or six-membered aromatic or non-aromatic ring fused to the ring to which Rb and Rc are attached, the ring formed will generally be a five- or six-membered heterocycle selected from those listed above for Het, or will be a phenyl, cyclohexyl or cyclopentyl ring. Benzimidazolyl, 4-azabenzimidazolyl, 5-azabenzimidazolyl and substituted derivatives thereof are prefeπed moieties for the group attached to W in R4.
Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical, BrZ refers to the o-bromobenzyloxycarbonyl radical, CIZ refers to the o-chlorobenzyloxycarbonyl radical, Bn refers to the benzyl radical, 4-MBzl refers to the 4-methyl benzyl radical, Me refers to methyl, Et refers to ethyl, Ac refers to acetyl, Alk refers to Cj^alkyl, Nph refers to 1- or 2-naphthyl and cHex refers to cyclohexyl. MeArg is Nα-methyl arginine. Tet refers to 5-tetrazolyl. Certain reagents are abbreviated herein. DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethvlaminopyridine, DIEA refers to diisopropylethylamine, EDC refers to N-ethyl-N'(dimethylaminopropyl)- carbodiimide. HOBt refers to 1-hydroxybenzotriazole, THF refers to tetrahydrofuran, DMF refers to dimethyl formamide, NBS refers to N-bromo- succinimide, Pd/C refers to a palladium on carbon catalyst. DPPA refers to diphenylphosphoryl azide, BOP refers to benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, PPA refers to polyphosphoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate. incorporated herein by reference. Compounds of formula (I) are prepared by the methods described in Schemes
I and II, and methods analogous to those described therein. Scheme I
Figure imgf000019_0001
1 2
Figure imgf000019_0002
a) H2, Pt2θ, IN HCl; b) (Boc)2θ, IN NaOH, dioxane; c) oxalyl chloride, DMSO, Et3N, CH2CI2; d) aminomethylbenzimidazole dihydrochloride. KOH, NaBH3CN, MeOH.
An appropriately substituted pyridyl alcohol, such as 1-1 (available from Aldrich Chemical Co., Milwaukee, WI), is reduced under catalytic hydrogenation conditions with platinum oxide in aqueous HCl to give the corresponding piperidinyl alcohol, such as 1-2. Other useful methods to achieve this type of transformation can be found in Freifelder, "Practical Catalytic Hydrogenation", Chapter 9 (published by Wiley-Interscience). The nitrogen is protected as the t-butyl carbamate 1-3 by reaction with di-t-butyl dicarbonate in a mixture of aqueous NaOH and dioxane. The primary alcohol is oxidized to the corresponding aldehyde 1-4 following the general procedure of Swern (J. Org. Chem. 1976, 41, 3329). Many alternative methods of oxidizing a primary alcohol to the corresponding aldehyde have been described and can be found in such reference volumes as "Compendium of Organic Synthetic Methods" (published by Wiley-Interscience). The reductive animation of 1-4 with aminomethylbenzimidazole (available from Aldrich Chemical Co.,
Milwaukee, WI) is carried out following the general procedure of Borch (Org. Syn. 1972, 52, 124) to give the protected arginine mimic 1-5. Scheme II
Figure imgf000020_0001
Figure imgf000020_0002
a) EDC, HOBT H2O, Et3N, DMF; b) IN NaOH, MeOH; c) TFA, CH2C12.
A suitably protected benzazepine or benzodiazepine, such as II-l (prepared as described in Bondinell, et al., PCT application WO 93/00095, published January 7, 1993 and Bondinell, et al., PCT application WO 94/14776, published July 7, 1994) is converted to an activated form using, for example, EDC and HOBt, and the activated form is subsequently reacted with a suitably protected arginine mimic, such as 1-5 (prepared as above), in a suitable solvent such as DMF or C^C^- Depending on whether acid nuetralization is required, an added base, such as diisopropylethylamine, may be used. The methyl ester of II-2 is hydrolyzed with aqueous base, such as, NaOH in aqueous MeOH and the t-butyl carbamate is removed with a strong acid, such as TFA in CH2CI2 or HCl in dioxane. The intermediate carboxylate salt is acidified with a suitable acid, such as TFA or HCl to afford the carboxylic acid II-3.
The tricyclic core of the compounds of formula (II) are prepared as described in Bondinell, et al., PCT Application WO 97/01540, published January 16, 1997. Reference should be made to said patent application, the entire disclosure of which is incorporated by reference. The formula (II) compounds are prepared by methods analogous to those detailed in Scheme II. Coupling methods to form amide bonds are generally well known to the art. The methods of peptide synthesis generally set forth by Bodansky et al., THE PRACTICE OF PEPTIDE SYNTHESIS, Springer- Verlag, Berlin, 1984, Ali et al. in /. Med. Chem., 29, 984 (1986) and J. Med. Chem., 30, 2291 (1987) are generally illustrative of the technique and are incorporated herein by reference. Coupling reagents as used herein denote reagents which may be used to form amide bonds. Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, BOP reagent, HOBt, N- hydroxysuccinimide and oxalyl chloride are typical. Typically, the amine or aniline is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as N,N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine (DMAP). Other methods, such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine of a suitably protected amine, optionally in the presence of a base, are also suitable. For example, a protected Boc-amino acid or Cbz-amidino benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran(THF), in the pre sence of a base, such as N-methyl moφholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the
"activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid or aniline.
Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hvdrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic. succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li+, Na+, K+, Ca++, Mg++ and NH4+ are specific examples of cations present in pharmaceutically acceptable salts.
This invention also provides a pharmaceutical composition which comprises a compound according to formula (I) and a pharmaceutically acceptable carrier. Accordingly, the compounds of formula (I) may be used in the manufacture of a medicament. Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpynolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule. For rectal administration, the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
The compounds described herein which are antagonists of the vitronectin receptor, are useful for treating diseases wherein the underlying pathology is attributable to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology. Thus, the instant compounds are useful for the treatment of ostoeporosis, hypeφarathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency. The compounds of this invention are also believed to have utility as antitumor, antiinflammatory, anti-angiogenic and anti-metastatic agents, and be useful in the treatment of cancer, atherosclerosis and restenosis. In particular, the compounds of this invention are useful for inhibiting restenosis following angioplasty.
The compounds of this invention which inhibit fibrinogen binding provide a method of inhibiting platelet aggregation and clot formation in a mammal, especially a human, which comprises the internal administration of a compound of formula (I) and a pharmaceutically acceptable carrier. Indications for such therapy include acute myocardial infarction (AMI), deep vein thrombosis, pulmonary embolism, dissecting anurysm, transient ischemia attack (TIA), stroke and other infarct-related disorders, and unstable angina. Chronic or acute states of hyper-aggregability, such as disseminated intravascular coagulation (DIC), septicemia, surgical or infectious shock, post-operative and post-partum trauma, cardiopulmonary bypass surgery, incompatible blood transfusion, abruptio placenta, thrombotic thrombocytopenic puφura (TTP), snake venom and immune diseases, are likely to be responsive to such treatment. In addition, the compounds of this invention may be useful in a method for the prevention of metastatic conditions, the prevention or treatment of fungal or bacterial infection, inducing immunostimulation, treatment of sickle cell disease, and the prevention or treatment of diseases in which bone resoφtion is a factor.
This invention further provides a method for inhibiting the reocclusion of an artery or vein following fibrinolytic therapy, which comprises internal administration of a compound of formula (I) and a fibrinolytic agent. Administration of a compound of formula (I) in fibrinolytic therapy either prevents reocclusion completely or prolongs the time to reocclusion. When used in the context of this invention the term fibrinolytic agent is intended to mean any compound, whether a natural or synthetic product, which directly or indirectly causes the lysis of a fibrin clot. Plasminogen activators are a well known group of fibrinolytic agents. Useful plasminogen activators include, for example, anistreplase, urokinase (UK), pro-urokinase (pUK), streptokinase (SK), tissue plasminogen activator (tPA) and mutants, or variants, thereof. The compounds of this invention may also be used in vitro to inhibit the aggregation of platelets in blood and blood products, e.g., for storage, or for ex vivo manipulations such as in diagnostic or research use.
The compound is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resoφtion, or inhibit platelet aggregation or other such indication. The pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg. For acute therapy, parenteral administration is preferred. An intravenous infusion of the compound in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful. Typically, the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg. The compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day. The precise level and method by which the compounds are administered is readily determined by one routinely skilled in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
The compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
INHIBITION OF VITRONECTIN BINDING
Solid-Phase 'HJ-SK&F- 107260 Binding to
Figure imgf000024_0001
Human placenta or human platelet αvβ3 (0.1-0.3 mg/mL) in buffer T (containing 2 mM CaCl2 and 1% octylglucoside) was diluted with buffer T containing 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 (buffer A) and 0.05% NaN3, and then immediately added to 96-well ELISA plates (Corning, New York, NY) at 0.1 mL per well. 0.1 - 0.2 μg of αvβ3 was added per well. The plates were incubated overnight at 4°C. At the time of the experiment, the wells were washed once with buffer A and were incubated with 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
Compounds were dissolved in 100% DMSO to give a 2 mM stock solution, which was diluted with binding buffer (15 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM CaCl , 1 mM MnCl2, 1 mM MgCl2) to a final compound concentration of 100 μM. This solution is then diluted to the required final compound concentration. Various concentrations of unlabeled antagonists (0.001 - 100 μM) were added to the wells in triplicates, followed by the addition of 5.0 nM of [3H]-SK&F- 107260 (65 - 86 Ci/mmol).
The plates were incubated for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed once with 0.2 mL of ice cold buffer A in a well-to-well fashion. The receptors were solubilized with 0.1 mL of 1% SDS and the bound [3H]-SK&F- 107260 was determined by liquid scintillation counting with the addition of 3 mL Ready Safe in a Beckman LS Liquid Scintillation Counter, with 40% efficiency. Nonspecific binding of [3H]-SK&F- 107260 was determined in the presence of 2 μM SK&F-107260 and was consistently less than 1 % of total radioligand input. The IC50 (concentration of the antagonist to inhibit 50% binding of [3H]-SK&F- 107260) was determined by a nonlinear, least squares curve-fitting routine, which was modified from the LUNDON-2 program. The Kj (dissociation constant of the antagonist) was calculated according to the equation: Kj = ICSQ/( 1 + L/K<ι), where L and K<ι were the concentration and the dissociation constant of [3H]-SK&F- 107260, respectively.
Compounds of the present invention inhibit vitronectin binding to SK&F 107260 in the concentration range of about 4 to about 25 nM
INHIBITION OF RGD-MEDIATED αm»β3 BINDING
Purification of cubβ
Ten units of outdated, washed human platelets (obtained from Red Cross) were lyzed by gentle stirring in 3% octylglucoside, 20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 2 mM CaCl2 at 4°C for 2 h. The lysate was centrifuged at 100,000g for 1 h. The supernatant obtained was applied to a 5 mL lentil lectin sepharose 4B column (E.Y. Labs) preequilibrated with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaCl , 1% octylglucoside (buffer A). After 2 h incubation, the column was washed with 50 mL cold buffer A. The lectin-retained ocπbβ3 was eluted with buffer A containing 10% dextrose. All procedures were performed at 4°C. The απbβ3 obtained was >95% pure as shown by SDS polyacrylamide gel electrophoresis.
Incorporation of Ujibβi in Liposom.es A mixture of phosphatidylserine (70%) and phosphatidylcholine (30%)
(Avanti Polar Lipids) were dried to the walls of a glass tube under a stream of nitrogen. Purified c ibβ3 was diluted to a final concentration of 0.5 mg/mL and mixed with the phospholipids in a protein:phospholipid ratio of 1 :3 (w:w). The mixture was resuspended and sonicated in a bath sonicator for 5 min. The mixture was then dialyzed overnight using 12,000-14,000 molecular weight cutoff dialysis tubing against a 1000-fold excess of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaC12 (with 2 changes). The απbβ3-containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70°C until needed. Competitive Binding to 0([[t,β3
The binding to the fibrinogen receptor (απbβ3) was assayed by an indirect competitive binding method using [3H]-SK&F- 107260 as an RGD-type ligand. The binding assay was performed in a 96-well filtration plate assembly (Millipore Coφoration, Bedford, MA) using 0.22 um hydrophilic durapore membranes. The wells were precoated with 0.2 mL of 10 μg/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding. Various concentrations of unlabeled benzadiazapines were added to the wells in quadruplicate. [3H]-SK&F- 107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 μg of the purified platelet απbβ3-containing liposomes. The mixtures were incubated for 1 h at room temperature. The 0tπ β3- bound [3HJ-SK&F- 107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL). Bound radioactivity remaining on the filters was counted in 1.5 mL Ready Solve (Beckman Instruments, Fullerton, CA) in a Beckman Liquid
Scintillation Counter (Model LS6800), with 40% efficiency. Nonspecific binding was determined in the presence of 2 μM unlabeled SK&F- 107260 and was consistently less than 0.14% of the total radioactivity added to the samples. All data points are the mean of quadruplicate determinations. Competition binding data were analyzed by a nonlinear least-squares curve fitting procedure. This method provides the IC50 of the antagonists (concentration of the antagonist which inhibits specific binding of [ H]-SK&F- 107260 by 50% at equilibrium). The IC50 is related to the equilibrium dissociation constant (Ki) of the antagonist based on the Cheng and Prusoff equation: Ki = IC50/( l+L/Kd), where L is the concentration of [3HJ-SK&F- 107260 used in the competitive binding assay (4.5 nM), and Kd is the dissociation constant of [3HJ-SK&F- 107260 which is 4.5 nM as determined by Scatchard analysis.
Compounds of this invention inhibit [ H]-SK&F- 107260 binding with a Ki of about 8 to about 55 nM.
Inhibition of platelet aggregation may be measured by the method described in WO 93/00095 (PCT/US/92/05463). In vivo thrombus formation is demonstrated by recording the systemic and hemodynamic effects of infusion of the peptides into anesthetized dogs according to the methods described in Aiken et al., Prostaglandins, 19, 620 (1980). Vascular smooth muscle cell migration assay
The compounds of the instant invention were tested for their ability to inhibit the migration and proliferation of smooth muscle tissue in an artery or vein in order to assess their ability to prevent restenosis of an artery, such as that which typically occurs following angioplasty.
Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane with pores of 8 um (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 106 cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin. Incubation was carried out at 37°C in an atmosphere of 95% air/5% CO2 for 24 hr. After incubation, the non-migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured either by a) counting the number of cells that had migrated to the lower surface of the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
The efficacy of the compounds of formula (I) to prevent tumor growth may be determined using several transplantable mouse tumor models. See U. S. Patent Nos. 5,004,758 and 5,633,016 for details of these models.
The examples which follow are intended to in no way limit the scope of this invention, but are provided to illustrate how to make and use the compound of this invention. Many other embodiments will be readily apparent and available to those skilled in the art.
General
Nuclear magnetic resonance spectra were obtained using either a Bruker AM 250 or Bruker AC 400 spectrometer. Chemical shifts are reported in parts per milliom (δ) downfield from the internal standard tetramethylsilane. Mass spectra were taken on either VG 70 FE or VG ZAB HF instruments using fast atom bombardment (FAB) or electrospry-(ES) ionization techniques. Elemental analyses were performed by Quantitative Technologies Inc., Whitehouse, New Jersey.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical and preparative HPLC were carried out on Bechman Chromatographs. PRP-1® is a polymeric (styrene- divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada.
Example 1
Preparation of (S)-7-r /V-4-piperidinylethyl-A;-( 1 H-benzimidazol-2- ylmethyl)laminocarbonyll-2.3.4.5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid
a) N-t-Butoxycarbonyl-4-(2-hydroxyethyl)piperidine
To a solution of 4-(2-hydroxyethyl)pyridine (l .OOg, 8.12 mmol) in IN HCl (10 mL) in a Parr hydrogenation apparatus was added Pt2θ (10 mg). The mixture was hydrogenated at 50 psi for 7h. After venting the hydrogen, the catalyst was removed by filtration through celite and the celite rinsed with H2O (10 mL). Concentration of the combined filtrate afforded the crude 4-(2- hydroyethyl)piperidine. MS (ES+) m/z 129.9 (M+H+).
The crude material obtained above was dissolved in a mixture of dioxane (25 mL) and IN NaOH (25 mL). The resulting solution was cooled to 0°C and di-t- butyl dicarbonate (2.12 g, 9.71 mmol) was added. The reaction was allowed to warm to RT and after stirring overnight was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (50 mL) and dried over Na2SO4. Concentration gave a pale yellow oil (1.56 g) which was subjected to radial chromatography (solvent gradient 30% to 50% EtOAc/hexane, silica gel, 6 mm plate) to give 1.38g (74%) of the desired material as a clear oil. 1H NMR (400 MHz, CDCI3) δ 4.10 (broad s, 2H), 3.70 (dd, J = 11.8, 6.4 Hz, 2H), 2.58 (m, 2H), 1.70
b) 2-(4-/V-t-Butoxycarbonylpiperidine)acetaldehyde To a solution of oxalyl chloride (0.53 mL, 6.07 mmol) and DMSO (0.86 mL,
12.1 mmol) in CH2CI2 (15 mL) at -78°C was added rapidly a solution of N-t- butoxycarbonyl-4-(2-hydroxyethyl)piperidine (1.38 g, 6.03 mmol). The reaction was warmed to -15°C for 30 min. Et3N (1.68 mL, 12. o mmol) was added to this solution and the reaction was allowed to warm and maintained at RT for 3 h. The reaction was quenched by pouring into sat. NaHCO3 (10 mL) and extracting with CH2CI2 (3 x 15 mL). The combined organic extracts were dried over Na2SO4 and concentrated to give a pale green oil (1.42 g). Purification by radial chromatography (50% EtOAc/hexanes, silica gel, 6 mm plate) gave 1.08g (79%) of the desired product as a pale yellow oil. lU NMR (400 MHz, CDCI3) δ 9.79 (s, 1H), 4.10 (m, 2H), 2.70 (m, 2H0, 2.38 (d, J = 6-.7 Hz, 2H), 2.10 (m, 2H), 1.70 (m, 2H). 1.45 (s, 9H), 1.15 (m, 2H).
c) Λ^(4-Λ-t-Butoxycarbonylpiperidinylethyl)-Λ/-(lH-benzimidazol-2- ylmethyl)]amine
To aminomethylbenzimidazole dihydrochloride (1.31 g, 5.95 mmol) in MeOH (8 mL) was added KOH (0.67 g, 1 1.9 mmol). When the KOH had dissolved. a solution of 2-(4-N-t-butoxycarbonylpiperidine)acetaldehyde ( 1.08 g, 4.76 mmol) in MeOH (4 mL) was added. After 15 min at RT, NaCNBH (0.10 g, 1.59 mmol) was added portionwise. The reaction was allowed to proceed for 8 h and then concentrated to give a yellow residue. Radial chromatography (10% MeOH/CHCl3, silica gel, 6 mm plate) gave 0.76 g (45%) of the desried material as a pale yellow oil. MS (ES+) m z 359.3 (M+H+).
d) (S)-7-[[Λ^-(4- V-t-Butoxycarbonylpiperidinylethyl)-/V-(lH-benzimidazol-2- ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid, methyl ester Λ/-[(4-Λ/-r-Butoxycarbonylpiperidinylethyl)-iV-( lH-benzimidazol-2- ylmethyl)]amine (0.66 g, 1.84 mmol), methyl (S)-7-carboxy-2,3,4,5-tetrahydro-3- oxo-4-methyl-lH-l,4-benzodiazepine-2-acetate (0.54 g, 1.85 mmol), EDC (0.53 g, 2.76 mmol), HOBT (.38 g, 2.81 mmol) and Et3N (1.30 mL, 9.33 mmol) were combined in DMF (20 mL) and stirred at RT for 3 days. The solvent was evaporated and the product was isolated by radial chromatography (5%
MeOH/CHCl3, silica gel , 6 mm plate) to give 1.06 g of material which was deemed to be of sufficient purity by ^H NMR to be earned onto the next step. MS (ES+) m/z 633.3 (M+H+). e) (S)-7-[[N-4-Piperidinylethyl-N-(-lH-benzimidazol-2-ylmethyl)]aminocarbonyl]- 2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid
To (S)-7-[[/V-(4-Λ^-t-butoxycarbonylpiperidinylethyl)-jV-(lH-benzimidazol-2- ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid, methyl ester (1.06 g, 1.68 mmol) in EtOH (5 mL) was added IN NaOH (5 mL, 5 mmol). After stirring at RT for 4h, the reaction was made acidic to pH 3 with IN HCl and the solvent was evaporated. Azeotrope the residue from toluene to give the product acid as a pale yellow foam. This was carried on crude without further purification. MS (ES+) m/z 619.2 (M+H+). The crude acid obtained above was dissolved in CH2CI2 (10 mL) and TFA
(10 mL). After 2h at RT, the solvent was removed under reduced pressure to give an off-white foam. Flash chromatography (reverse phase silica gel, step gradient: H2O + 0.1% TFA, 5% CH3CN/H2O + 0.1% TFA, 10% CH CN H2O + 0.1% TFA, 20% CH CN/H 0 + 0.1 % TFA) gave 0.38 g of desired product as a white fluffy solid which was pure by HPLC analysis. MS (ES+) m/z 519.4 (M+H+). Anal.
(c28H34N6°4-2CF3co2H'2H2θ) calcd: C, 49.1 1; H, 5.15; N, 10.74. Found: C, 49.26; H, 5.00; N, 10.59.
Example 2
Preparation of (S)-7-[[A --piperidinylpropyl-A ( lH-benzimidazol-2- ylmethyl)laminocarbonyll-2.3.4,5-tetrahydro-4-methyl-3-oxo-lH-1.4- benzodiazepine-2-acetic acid
a) Λ-t-Butoxycarbonyl-4-(3-hydroxypropyl)piperidine
In a manner analogous to Example 1(a), 4-pyridinepropanol (2.21 g, 15.5 mmol) gave 3.97 g of the desired product which was used without further purification. !H NMR (250 MHz, CDCI3) 54.10 (m, 2H), 3.60 (m, 2H), 2.65 (m,
2H), 1.70 - 1.00 (m, 9H), 1.45 (s, 9H).
b) 3-(4-N-t-Butoxycarbonylpiperidine)propanal
In a manner analogous to Example 1(b), Λf-t-butoxycarbonyl-4-(3- hydroxypropyl)piperidine (l.OOg, 4.11 mmol) gave 0.68 g of the desired product as a clear oil after flash chromatography (20% to 50% EtOAc/hexanes, silica gel). 1H NMR (250 MHz, CDCI3) δ 9.78 (s, IH), 4.09 (m, 2H), 2.66 (m, 2H), 2.47 (m, 2H),
1.70 - 1.35 (m, 5H), 1.45 (s, 9H), 1.10 (m, 2H). c) N-[(4-N-t-Butoxycarbonylpiperidinylpropyl)-jV-(lH-benzimidazol-2- ylmethyl)] amine
In a manner analogous to Example 1(c), 3-(4-Λ/-t-butoxycarbonylpiperidine)- propanal (0.12 g, 0.50 mmol), aminomethylbenzimidazole dihydrochloride (0.14 g, 0.64 mmol), KOH (0.07 g, 1.25 mmol) and NaCNBH ( 12.0 mg, 0.19 mmol) gave 0.05 g of the desired product as a pale yellow oil after flash chromatography (5% MeOH/CHCl3, silica gel). MS (ES+) m z 373.4 (M+H+).
d) (S)-7-[[N-(4-/V-t-Butoxycarbonylpiperidinylpropyl)-Λ-(lH-benzimidazol-2- ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid, methyl ester.
In a manner analogous to Example 1(d), N-[(4-/V-t- butoxycarbonylpiperidinyl-propyl)-/^-(lH-benzimidazol-2-ylmethyl)]amine (0.05 g, 0.13 mmol), methyl (S)-7-carboxy-2,3,4,5-tetrahydro-3-oxo-4-methyl- lH-l,4- benzodiazepine-2-acetate (0.04 g, 0.13 mmol), EDC (0.04 g, 0.21 mmol), HOBT (0.03 g, 0.22 mmol) and Et3N (0.09 mL, 0.64 mmol) gave 0.14 g of the desired material after flash chromatography (5% MeOH/CHCl3, silica gel). MS (ES+) m z 647.5 (M+H+).
e) (S)-7-[[N-4-Piperidinylpropyl-N-(lH-benzimidazol-2-ylmethyl)]aminocarbonyl]- 2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l ,4-benzodiazepine-2-acetic acid
In a manner analogous to Example 1(e), (S)-7-[[N-(4-N-r-butoxycarbonyl- piperidinylpropyl)-/V-( lH-benzimidazol-2-ylmethyl)]aminocarbonyl]-2, 3,4,5- tetrahydro-4-methyl-3-oxo- lH- l ,4-benzodiazepine-2-acetic acid, methyl ester (0.12 g, 0.19 mmol) gave 63.5 mg of the desired product as white solid after flash chromatography (step gradient: H2O + 0.1% TFA; 5% CH3CN/H2O + 0.1% TFA; 10% CH CN/H2O + 0.1 % TFA, reverse-phase silica gel). MS (ES+) m z 533.5 (M+H+). Anal. (C29H36N6O4-2CF3CO2H-2H2O) calcd: C, 49.75; H, 5.31 ; N, 10.55. Found: C, 49.64; H, 4.92; N, 10.24.
- Example 3
Preparation of (S)-7-rW-(4-piperidinylpropyn-N-(lH-4.5.6.7- tetrahydrobenzimidazoI-2-ylmethyl)laminocarbonyn-2,3.4,5-tetrahydro-4-methyl-3- oxo- 1 H- 1 ,4-benzodiazepine-2-acetic acid
a) 3-(4-Pyridine)propanal
In a manner analogous to Example 1(b), 4-pyridinepopanol (1.76 g, 12.8 mmol), DMSO (2.73 mL, 38.5 mmol), oxalyl chloride (1.68 mL, 19.3 mmol) and Et3N (8.86 mL, 63.5 mmol) gave 1.66 g of the desired product as a dark residue which was used without further purification. MS (136.0 (M+H+).
b) N-[(4-Pyridinylpropyl)-/V-( 1 H-benzimidazol-2-ylmethyl)]amine
In manner analogous to Example 1(c), 3-(4-pyridine)propanal ( 1.66 g, 12.3 mmol), aminomethylbenzimidazole dihydrochloride (3.38 g, 15.4 mmol), KOH
(1.90 g, 33.9 mmol) and NaCNBH3 (0.26 g, 4.14 mmol) gave 1.97 g of the desired product as a clear oil after flash chromatography (10% to 15% MeOH/EtOAc, silica gel). MS (ES+) m/z 267.4 (M+H+).
c) (S)-7-[[Λ^-(4-Pyridinylpropyl)-Λ^-(lH-benzimidazol-2-ylmethyl)]aminocarbonyl]- 2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid, methyl ester
In a manner analogous to Example 1(d), N-[(4-pyridinylpropyl)-iV-(lH- benzimidazol-2-ylmethyl)]amine (0.41 g, 1.54 mmol), methyl (S)-7-carboxy-2, 3,4,5- tetrahydro-3-oxo-4-methyl-lH-l,4-benzodiazepine-2-acetate (0.38 g, 1.30 mmol), EDC (0.38 g, 1.98 mmol), HOBT (0.27 g, 1.99 mmol), and Et2N (0.90 mL, 6.46 mmol) gave 0.73 g of the desired compound as a clear oil after flash chromatography (10% MeOH/CHCl3, silica gel). MS(ES+) m/z 541.5 (M+H+).
d) (S)-7-[[ V-(4-Piperidinylpropyl)-/V-(lH-4,5,6,7-tetrahydrobenzimidazol-2- ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid, methyl ester
A Parr hydrogenation apparatus was charged with (S)-7-[[/v~-(4- pyridinylpropyl)-/V-(lH-benzimidazol-2-ylmethyl)]aminocarbonyl]-2, 3,4,5- tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid, methyl ester (0.10 g, 0.18 mmol), IN HCl (0.18 mL) and PtO2 (10 mg) in MeOH (lmL). The material was hydrogenated at 40 psi and RT for 8h. After venting the hydrogen and removing the catalyst by filtration, the solvent was evaporated under reduced pressure to give 0.09 g of the desired material as a white solid. This was used in the next step without further purification. MS (ES+) m z 551.5 (M+H+).
e) (S)-7-[[N-(4-Piperidinylpropyl)-N-(lH-4,5,6,7-tetrahydrobenzimidazol-2- ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4- benzodiazepine-2-acetic acid
To the crude (S)-7-[[N-(4-Piperidinylpropyl)-Λ'-(lH-4,5,6,7- tetrahydrobenzimidazol-2-ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3- oxo-lH-l,4-benzodiazepine-2-acetic acid, methyl ester (0.09 g, 0.16 mmol) in EtOH (3 mL) was added IN NaOH (0.54 mL). After stirring at RT for 7h, the reaction mixture was made acidic (pH = 3) with IN HCl and concentrated to give a white residue. Trituration with EtOH gave the product as a white precipitate which was collected and dried under vacuum to give 0.05 g of the desired product as a white solid. MS(ES+) m/z 537.5 (M+H+).
Example 4
Preparation of (+/-)-2,3A5-tetrahvdro-3-oxo-8-r[A --piperidinylpropyl-jV-(lH- benzimidazol-2-ylmethyl)1aminocarbonvn-2-methyl-lH-2-benzazepine-4-acetic acid
a) (+/-)-2,3,4,5-Tetrahydro-3-oxo-8-[[N-(4-/V-t-butoxycarbonylpiperidinylpropyl-/V- (lH-benzimidazol-2-ylmethyl)]aminocarbonyl]-2-methyl-lH-2-benzazepine-4-acetic acid, methyl ester
In a manner analogous to Example 1(d), /V-[(4-/V-t- butoxycarbonylpiperidinyl-propyl)-jV-(lH-benzimidazol-2-ylmethyl)]amine (0.14 g, 0.38 mmol), (+/-)-methyl 2,3,4,5-tetrahydro-3-oxo-8-carboxy~2-methyl-lH-2- benzazepine-4-acetate (0.12 g, 0.41 mmol), EDC (0.1 1 g, 0.57 mmol), HOBT (0.08 g, 0.59 mmol) and Et3N (0.26 mL, 1.87) gave 0.19 g of the desired product after radial chromatography (10% MeOH/EtOAc, silica gel, 2 mm plate). MS (ES+) m/z 646.5 (M+H+).
b) (+/-)-2,3,4,5-tetrahydro-3-oxo-8-[[/V-4-piperidinylpropyl-N-(lH-benzimidazol-2- ylmethyl)]aminocarbonyl]-2-methyl- lH-2-benzazepine-4-acetic acid
In a manner analogous to Example 1(e), (+/-)-2,3,4,5-tetrahydro-3-oxo-8- [[/V-(4-N-f-butoxycarbonylpiperidinylpropyl-/V-( 1 H-benzimidazol-2- ylmethyl)]aminocarbonyl]-2-methyl-lH-2-benzazepine-4-acetic acid, methyl ester (0.19 g, 0.29 mmol) gave 0.23 g of the desired product as a white foam after reverse phase flash chromatography (step gradient: H2O + 0.1% TFA then 30% CH3CN/H2O + 0.1% TFA, Analytichem Bond-Elut® C-8 column, 50 mL size). MS (ES+) m/z 532.4 (M+H+). Anal. (C3θH37N5θ4-2CF3Cθ2H2H2O) calcd: C, 51.32; H, 5.45; N, 8.80. Found: C, 51.24; H, 5.15; N, 8.47.
Example 5
Oral Dosage Unit Composition
A tablet for oral administration is prepared by mixing and granulating 20 mg of sucrose, 150 mg of calcium sulfate dihydrate and 50 mg of the compound of Example 1 with a 10% gelatin solution. The wet granules are screened, dried, mixed with 10 mg starch, 5 mg talc and 3 mg stearic acid; and compressed into a tablet.
The above description fully discloses how to make and use the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incoφorated herein by reference as though fully set forth.

Claims

What is claimed is:
1. A compound according to formulae (I) or (II):
Figure imgf000035_0001
wherein:
AisNR', CHR', OorS; Aj is C orN;
X1 and X2 are C=0 or CHR', with the proviso that only one of X1 or X2 is
C=O;
Figure imgf000035_0002
-membered heteroaromatic or six-membered aromatic ring optionally substituted by R1 ' ;
R
\
N-Y CH-
R* is " ,»/ or " ;
EisO, S, C(0)orC(S);
Y is C(O), C(S) or CH2;
R1 is R7, or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl, D-C3-4oxoalkenyl, D-C3-4oxoalkynyl, D-Cι_4aminoalkyl, D-C3_4aminoalkenyl, D-C3_4aminoalkynyl, optionally substituted by any accessible combination of one or more of R11 or ;
R2 is -(CH2)t-CO2R3;
R3 is H, C galkyl or (CHR r; R4 is
Figure imgf000036_0001
W is -(CHRg)a-U- (CHRg)b-;
U is absent or CO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONR1, NR1 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O) NRg, NRgS(O)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg2O, OCRg2, C≡C or CRg=CRg;
G is NRe, S or O;
Rg is H, Ci.galkyl, Het-Cθ-6alkyl, C3_7cycloalkyl-Co-6alkyl or Ar-Co-6alkyl;
Rk is Rg, -C(O)Rg, or -C(O)ORf; R1 is is H, Ci .βalkyl, Het-Cø.βalkyl, C3-7cycloalkyl-Co-6alkyl,
Ar-Co-6alkyl, or .galkyl substituted by one to three groups chosen from halogen,
CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2;
Rf is H, Cι_6alkyl or Ar-C ^alkyl; Re is H, Cι„6 lkyl, Ar-Cj.galkyl, Het-C galkyl, C3-7cycloalkyl-Cι_6alkyl, or (CH2)kCO2Rg;
Rb and Rc are independently selected from H, C j.galkyl, Ar-CQ-όalkyl,
Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, ORf, S(O)kRf, CORf,
NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3,
Cj^alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2, CO(NRf)2, and
CH2N(Rf)2', or methylenedioxy; θ Q^> Q^ and Q4 are independently N or C-RY. provided that no more than one of QΛ Q2, Q3 and Q4 is N;
RY is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO , -CF3, CF3S(O)r, -CO2Rg,
-CORg or -CONRg2, or C ι_6alkyl optionally substituted by halo, -ORg, -SRg, -CN,
-NRgR", -NO2, -CF3, R'S(O)r, -CO2Rg, -CORg or -CONRg ;
R5 is W'-(CR'2)q-Z-(CR'RlO)rU'-(CR'2)s; U' is absent or CO, CR , C(=CR'2), S(O)n, O, NR', CR'OR, CR'(OR")CR'2,
CR' CR'(OR"), C(O)CR'2, CR'2C(O), CONR', NR'CO, OC(O), C(O)O, C(S)O,
OC(S), C(S)NR', NR'C(S), S(O)nNR', NR'S(0)n, N=N, NR'NR', NR'CR'2,
NR'CR'2, CR'2O, OCR2, c≡≡ c or CR'=CR;
W' is R'R'N-, RTrNRN-, RTΓNRNCO-, R' NR'NC(=NR , R'2N R'2 N NR" NR' R'ONR'C(=NR , R13 JL N- , R'2 N X N- f R'3 ^ x NR'- , R"R'N x Y, NR' NR14
R"R'N \ A NR'-X-. R"R'N A NR'- or Θ;
X is N=CR', C(O) or O; Y is absent, S or O;
Z is (CH2)t, Het, Ar or C3-7cycloalkyl; R7 is -COR8, -COCR'2R9, -C(S)R8, -S(O)mOR', -S^mNRTl", -PO(OR'),
-PO(OR')2, -B(OR')2, -NO2 and Tet;
R8 is -OR', -NR'R", -NR'SO2R', -NR'OR', -OCR'2C(O)OR', -OCR'2OC(O)- R', -OCR'2C(O)NR'2 or CF3;
R9 is -OR', -CN, -S(O)rR', S(O)mNR'2, -C(O)R' C(O)NR'2 or -CO2R'; R 10 is H, C 1 _4alkyl or -NR'R" ; each R1 1 independently is H, halo, -OR12, -CN, -NR'R12, -NO2, -CF3, CF3S(O)r, -CO2R', -CONR'2, D-Cø-6alkyl-, D-Ci-6oxoalkyl-, D-C2-6alkenyl-, D-C2-6alkynyl-, D-Cθ-6alkyloxy-, D-Cθ-6alkylamino- or D-Cθ-6alkyl-S(O)r;
R12 is R', -C(O)R', -C(O)NR'2, -C(O)OR15, -S(O)mR' or S(O)mNR'2; R13 is R', -CF3, -SR', or -OR';
R14 is R', C(O)R', CN, NO2, SO2R' or C(O)OR15;
R15 is H, Ci-6alkyl or Ar-Cθ-4alkyl;
D is H, C3-6cycloalkyl, Het or Ar;
R' is H, Ci-6alkyl, Ar-Cθ-6alkyl or C3_6cycloalkyl-Cθ-6alkyl; R" is R -C(O)R' or -C(O)OR';
R'" is H, Ci.galkyl, Ar-Co-6alkyl, Het-Co-6alkyl, or C3-6cycloalkyl-Co- galkyl, halogen, CF3, ORf, S(O)kRf, CORf, N02, N(Rf)2; CO(NRf)2, CH N(Rf)2; n is 0 to 3; q is 0 to 3; t is 0 to 2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1 ; and v is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
2. A compound according to formula (la):
Figure imgf000038_0001
wherein:
A is NR', CHR', O or S;
X1 and X2 are C=O or CHR', with the proviso that only one of X1 or X2 is C=O; Y is C(O), C(S) or CH2;
R1 is R7, or D-Co-4alkyl, D-C2-4alkenyl, D-C2-4alkynyl, D-C3-4oxoalkenyl, D-C3-4oxoalkynyl, D-Cι _4aminoalkyl, D-C3_4aminoalkenyl, D-C3_4aminoalkynyl, optionally substituted by any accessible combination of one or more of R11 or R7;
R2 is -(CH2)rCO2R3;
R3 is H, Cι_6alkyl or (CHR Ar;
Figure imgf000039_0001
W is -(CHRg)a-U- (CHRg)b-; U is absent or CO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg,
CRg(ORk)CRg , CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONR1, NR1 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg2O, OCRg2, C≡C or CRg=CRg;
G is NRe, S or O;
Rg is H, C^.galkyl, Het-CQ-6alkyl, C3-7cycloalkyl-Co-6alkyl or Ar-Co-6alkyl;
Rk is Rg, -C(O)Rg, or -C(O)ORf;
RΪ is is H, Ci .galkyl, Het-Co_6alkyl, C3-7cycloalkyl-Co-6alkyl, Ar-Co-6 lkyl, or C^alkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2; Rf is H, Cj.galkyl or Ar-C galkyl;
Re is H, C^alkyl, Ar-C ^galkyl, Het-C^alkyl, C3_7cycloalkyl-Cι_6alkyl, or (CH2)kCO2Rg;
Rb and Rc are independently selected from H, C^alkyl, Ar-Co-6alkyl, Het-Co-6alkyl, or C3-6cycloalkyl-Co-6alkyl. halogen, CF , ORf. S(O) Rf, COR , NO2, N(Rf)2, CO(NRf)2, CH2N(R )2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, Cι_4alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2, CO(NRf) , and CH2N(Rf)2; or methylenedioxy; Q1, Q2, Q3 and Q4 are independently N or C-RY, provided that no more than one of Q1 , Q2, Q3 and Q4 is N;
Ry is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, CF3S(O)r, -CO2Rg, -CORg or -CONRg , or C i-6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR", -NO2, -CF , R'S(O)r, -CO2Rg, -CORg or -CONRg2; R5 is W'-(CR'2)q-Z-(CR'R 0)rU'-(CR'2)s;
U' is absent or CO, CR'2, C(=CR'2), S(O)n, O, NR', CR'OR, CR'(OR")CR'2,
CR'2CR'(OR"), C(O)CR'2, CR'2C(O), CONR', NR'CO, OC(O), C(O)O, C(S)O,
OC(S), C(S)NR , NR'C(S), S(O)nNR', NR'S(O)n, N=N, NRNR', NR'CR'2,
NR'CR'2, CR'2θ, OCR'2, C≡ c or CR'=CR; '2NRNC(=NR')-, NR' R'- , R"R'N X Y,
Figure imgf000040_0001
X is N=CR', C(O) or O; Y is absent, S or O; Z is (CH2)t, Het, Ar or C3_7cycloalkyl; R7 is -COR8, -COCR'2R9, -C(S)R8, -S(O)mOR', -S(O)mNR'R", -PO(OR'), -PO OR'tø, -B(OR 2, -NO2 and Tet;
R8 is -OR', -NR'R", -NR'SO2R', -NR'OR', -OCR'2C(O)OR', -OCR'2OC(O)- R', -OCR'2C(O)NR'2 or CF3; R9 is -OR', -CN, -S(O)rR', S(O)mNR'2, -C(O)R' C(O)NR'2 or -CO2R';
R10 is H, Ci-4alkyl or -NR'R";
R11 is H, halo, -OR12, -CN, -NR'R12, -NO2, -CF3, CF3S(O)r, -CO2R', -CONR'2, D-Co-6alkyl-, D-Ci-6oxoalkyl-, D-C2-6alkenyl-, D-C2-6alkynyl-, D-Co-6alkyloxy-, D-Cθ-6alkylamino- or D-Cθ-6alky1"S(O)r-; R12 is R', -C(O)R', -C(O)NR'2, -C(O)OR15, -S(O)mR' or S(O)mNR'2;
R13 is R', -CF3, -SR', or -OR';
R14 is R', C(O)R', CN, NO2, SO2R' or C(O)OR15;
R15 is H, Cι_6alkyl or Ar-Cθ-4alkyl;
D is H, C3-6cycloalkyl, Het or Ar; R' is H, Ci-6alkyl, Ar-Cθ-6alkyl or Cs-όcycloalkyl-Co-όa y1'.
R" is R', -C(O)R' or -C(O)OR';
R'" is H, Ci.galkyl, Ar-Co_6alkyl, Het-CQ-όalkyl, or C3-6cycloalkyl-Co_ 6alkyl, halogen, CF3, ORf, S(O)kRf, COR , NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2; n is 0 to 3; q is 0 to 3; t is 0 to 2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1 ; and v is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 wherein Y is C(O).
4. The compound according to claim 2 wherein X1 is CH2 and X2 is C=O.
5. The compound according to claim 2 wherein A is NR', in which R' is H or C^alkyl.
6. The compound according to claim 5 wherein R1 is D-CQ-4alkyl, optionally substituted by R 1.
7. The compound according to claim 6 wherein R1 is H, CH3, CH2CH3, CH2CF3, (CH2)ι_2phenyl, in which the phenyl group is unsubstituted or substituted by ^alkyl, Cι.4alkoxy, C1.4aU.thio, CF3, OH, or halo.
8. A compound according to claim 2 wherein R5 is chosen from:
Figure imgf000042_0001
Figure imgf000042_0002
R"HNC(=NH)NH-(CH2)3(CHR10)-, and R"HN-(CH2)5-, wherein E is N or CH, and R20 is hydrogen, amino, mono or di-Cι.4alkylamino, hydroxy or Ci-4alkyl.
9. A compound according to claim 8 wherein R5 is
Figure imgf000042_0003
in which R" is H.
10. A compound according to claim 2 wherein the group attached to W in R4 is chosen from:
Figure imgf000043_0001
wherein G is NH and Rb and Rc are joined to form a cyclohexyl, phenyl or pyridyl ring and R', R" and Rg are each H and s is 0 or 1.
1 1. A compound according to claim 2 wherein R4 is:
Figure imgf000043_0002
12. A compound according to claim 1 1 wherein R4 is:
Figure imgf000043_0003
13. A compound according to claim 2 which is: (S)-7-[[N-(4-pyridinylpropyl)-N-(lH-benzimidazol-2-ylmethyl)]- aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid;
(S)-7-[[/V-4-piperidinylpropyl-N-(lH-benzimidazol-2-ylmethyl)]- aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid;
(S)-7-[[N-(4-piperidinylpropyl)-/V-(lH-4,5,6,7-tetrahydro- benzimidazol-2-ylmethyl)]aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH- 1 ,4-benzodiazepine-2-acetic acid; or (+/-)-2,3,4,5-tetrahydro-3-oxo-8-[[jV-4-piperidinylpropyl-N-(lH- benzimidazol-2-ylmethyl)]aminocarbonyl]-2-methyl-lH-2-benzazepine-4-acetic acid; or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound according to any one of claims 1-13 and a pharmaceutically acceptable carrier.
15. A method of inhibiting the fibrinogen receptor and the vitronectin receptor comprising administering a compound according to any one of claims 1-13.
16. A method of for treating atherosclerosis or restenosis following angioplasty in a mammal comprising administering a compound according to any one of claims 1-13.
17. A compound according to any one of claims 1 to 13 for use as a medicament.
18. The use of a compound as defined in any one of claims 1 to 13 in the manufacture of a medicament for the treatment of diseases in which the inhibition of the fibrinogen receptor and the vitronectin receptor is indicated.
19. The use of a compound as defined in any one of claims 1 to 13 in the manufacture of a medicament for the treatment of atherosclerosis or restenosis.
PCT/US1998/016246 1997-08-04 1998-08-04 Integrin receptor antagonists WO1999006049A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000504863A JP2001511452A (en) 1997-08-04 1998-08-04 Integrin receptor antagonist
EP98938357A EP1007051A4 (en) 1997-08-04 1998-08-04 Integrin receptor antagonists
CA002298544A CA2298544A1 (en) 1997-08-04 1998-08-04 Integrin receptor antagonists
AU86897/98A AU8689798A (en) 1997-08-04 1998-08-04 Integrin receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5470397P 1997-08-04 1997-08-04
US6352697P 1997-10-29 1997-10-29
US60/054,703 1997-10-29
US60/063,526 1997-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09485178 A-371-Of-International 2000-02-03
US10/020,012 Continuation US20020055499A1 (en) 1997-08-04 2001-12-12 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
WO1999006049A1 true WO1999006049A1 (en) 1999-02-11

Family

ID=26733371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016246 WO1999006049A1 (en) 1997-08-04 1998-08-04 Integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP1007051A4 (en)
JP (1) JP2001511452A (en)
AU (1) AU8689798A (en)
CA (1) CA2298544A1 (en)
WO (1) WO1999006049A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
WO2000035887A3 (en) * 1998-12-18 2000-11-16 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6232308B1 (en) 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists
WO2001093840A2 (en) * 2000-06-06 2001-12-13 Basf Ag Ligands of integrin receptors
WO2001096312A1 (en) * 2000-06-14 2001-12-20 Basf Aktiengesellschaft Integrin ligands
EP1171428A1 (en) * 1999-04-19 2002-01-16 SmithKline Beecham Corporation Fab i inhibitors
WO2002014320A2 (en) * 2000-08-11 2002-02-21 Basf Aktiengesellschaft Novel substituted diaryl azepine derivatives as integrin ligands
EP1208101A1 (en) * 1999-08-06 2002-05-29 SmithKline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1341497A2 (en) * 2000-11-02 2003-09-10 SmithKline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
WO2009063990A1 (en) 2007-11-16 2009-05-22 Ube Industries, Ltd. Benzazepinone compound
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
KR20220115062A (en) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 Pharmaceutical Composition For Treating and Preventing Osteoporosis Comprising Compounds of Chromone Scaffold
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024119A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
ATE238996T1 (en) * 1995-06-29 2003-05-15 Smithkline Beecham Corp INTEGRIN RECEPTOR ANTAGONISTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024119A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1007051A4 *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052673B2 (en) 1998-03-31 2006-05-30 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US7332149B1 (en) 1998-12-18 2008-02-19 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7321045B2 (en) 1998-12-18 2008-01-22 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7090828B2 (en) 1998-12-18 2006-08-15 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A3 (en) * 1998-12-18 2001-01-18 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US7018611B2 (en) 1998-12-18 2006-03-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6818201B2 (en) 1998-12-18 2004-11-16 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6558649B1 (en) 1998-12-18 2003-05-06 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6743412B2 (en) 1998-12-18 2004-06-01 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6689337B2 (en) 1998-12-18 2004-02-10 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035887A3 (en) * 1998-12-18 2000-11-16 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6683163B2 (en) 1998-12-18 2004-01-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035488A3 (en) * 1998-12-18 2000-11-09 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6232308B1 (en) 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists
JP2002542235A (en) * 1999-04-19 2002-12-10 スミスクライン・ビーチャム・コーポレイション FabI inhibitor
JP4647791B2 (en) * 1999-04-19 2011-03-09 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI inhibitor
EP1171428A1 (en) * 1999-04-19 2002-01-16 SmithKline Beecham Corporation Fab i inhibitors
EP1171428A4 (en) * 1999-04-19 2004-09-15 Affinium Pharm Inc Fab i inhibitors
EP1208101A4 (en) * 1999-08-06 2003-03-19 Smithkline Beecham Corp Vitronectin receptor antagonists useful for the treatment of strokes
EP1208101A1 (en) * 1999-08-06 2002-05-29 SmithKline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
WO2001093840A3 (en) * 2000-06-06 2002-08-08 Basf Ag Ligands of integrin receptors
WO2001093840A2 (en) * 2000-06-06 2001-12-13 Basf Ag Ligands of integrin receptors
WO2001096312A1 (en) * 2000-06-14 2001-12-20 Basf Aktiengesellschaft Integrin ligands
US7279468B2 (en) 2000-06-14 2007-10-09 Abbott Gmbh & Co. Kg Integrin ligands
WO2002014320A3 (en) * 2000-08-11 2002-07-25 Basf Ag Novel substituted diaryl azepine derivatives as integrin ligands
WO2002014320A2 (en) * 2000-08-11 2002-02-21 Basf Aktiengesellschaft Novel substituted diaryl azepine derivatives as integrin ligands
EP1341497A2 (en) * 2000-11-02 2003-09-10 SmithKline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2335733A1 (en) 2006-01-18 2011-06-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP2441464A1 (en) 2007-01-18 2012-04-18 Merck Patent GmbH Specific therapy and medicament using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
EP2578225A1 (en) 2007-07-18 2013-04-10 Merck Patent GmbH Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
WO2009063990A1 (en) 2007-11-16 2009-05-22 Ube Industries, Ltd. Benzazepinone compound
US8377922B2 (en) 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound
KR20100106391A (en) 2007-11-16 2010-10-01 우베 고산 가부시키가이샤 Benzazepinone compound
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
KR20220115062A (en) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 Pharmaceutical Composition For Treating and Preventing Osteoporosis Comprising Compounds of Chromone Scaffold
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Also Published As

Publication number Publication date
CA2298544A1 (en) 1999-02-11
AU8689798A (en) 1999-02-22
JP2001511452A (en) 2001-08-14
EP1007051A1 (en) 2000-06-14
EP1007051A4 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
WO1999006049A1 (en) Integrin receptor antagonists
AU733417B2 (en) Vitronectin receptor antagonists
US5741804A (en) Substituted benzimazoles which inhibit platelet aggrecation
WO1996026190A1 (en) Integrin receptor antagonists
US6239138B1 (en) Vitronectin receptor antagonist
EP0674623B1 (en) Bicyclic fibrinogen antagonists
US6159964A (en) Vitronectin receptor antagonists
EP0762882A1 (en) Vitronectin receptor antagonists
US6117910A (en) Bicyclic fibrinogen antagonists
WO1994029273A1 (en) Bicyclic fibrinogen antagonists
EP0869787A1 (en) Vitronectin receptor antagonists
CZ292925B6 (en) Integrin receptor antagonists, process of their preparation, pharmaceutical composition in which the antagonists are comprised and use thereof
US5977101A (en) Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
WO1999011626A1 (en) Integrin receptor antagonists
US5726192A (en) Platelet aggregation inhibiting compounds
US6008213A (en) Integrin receptor antagonists
US6028087A (en) Platelet aggregation inhibiting compounds
US6825188B2 (en) Vitronectin receptor antagonists
US6403578B1 (en) Bicyclic fibrinogen antagonists
US20020055499A1 (en) Integrin receptor antagonists
WO2000007544A2 (en) Vitronectin receptor antagonists
CA2124169A1 (en) Chemical compounds
US6458784B1 (en) Vitronectin receptor antagonists
NZ260616A (en) Platelet aggregation inhibitors optionally containing a gly-asp unit and pharmaceutical compositions
PL191595B1 (en) Antagonistic integrin receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ AM AZ BY KG KZ MD RU TJ TM CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998938357

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2298544

Country of ref document: CA

Ref country code: CA

Ref document number: 2298544

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09485178

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998938357

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998938357

Country of ref document: EP